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ABSTRACT
Dutch type periodic fever (DPF) is an autosomal recessive hereditary fever syndrome. Cases
have been reported worldwide, the majority from France and The Netherlands. From infancy
the patients suffer fever attacks that recur every 2-8 weeks, often precipitated by
immunizations, infections or emotional stress. Fever lasts 2-7 days and can be accompanied
by malaise, headache, diarrhea, abdominal pain, vomiting, skin rashes, arthralgia, arthritis,
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tender lymphadenopathy, hepatosplenomegaly, and oral and genital ulcers. Labarotory
evaluation during fever shows granulocytosis and elevated acute phase reactants. DPF is
caused by a deficiency of the enzyme mevalonate kinase (MK). Besides DPF, the spectrum of
MK deficiency includes a severe phenotype, mevalonic aciduria (MA). MA patients have less
residual MK activity, leading to substantially higher urinary mevalonic acid excretion than in
DPF. Mevalonic aciduria is characterized by mental retardation and dysmorphic features in
addition to the clinical features of DPF. At the genomic level, several mutations of varying
severity have been identified. The DPF phenotype is caused by one particular mild missense
mutation. Most patients are compound heterozygotes for this mutation and a more severe
mutation. The mechanism by which MK deficiency leads to fever is not understood. The vast
majority of DPF patients have persistently elevated serum IgD and can be classified as
having hyperimmunoglobulinemia D and periodic fever syndrome (HIDS). Conversely, most
HIDS patients have MK deficiency and hence DPF, but the two disorders do not overlap
entirely.
Introduction
The first reports of children with recurrent febrile attacks in the presence of an abnormally
high serum IgD concentration were published in 1984 (1). The first detailed description of this
disorder, was published by van der Meer et al. (2), who introduced the term
hyperimmunoglobulinemia D and periodic fever syndrome (HIDS). Most patients have been
of Dutch extraction, although cases have been reported worldwide (3). Hence, the
disease is also known as Dutch type periodic fever (DPF, MIM#260920). Inheritance is
autosomal recessive. The first febrile crises usually occur in infancy and recur at varying
intervals. The crises are typically triggered by infections and childhood immunizations. In
addition to fever the patients often experience malaise, chills, headache, arthralgias, nausea,
abdominal pain, and diarrhea, and show cutaneous rashes, hepatosplenomegaly, tender
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cervical lymphadenopathy, and frank arthritis (3). Granulocytosis and elevated acute phase
reactants during attacks reflect an acute inflammatory reaction, but a satisfactory explanation
for these findings is lacking. Linkage analysis excluded the gene affected in FMF as a
candidate involved in the etiology of HIDS (4). The cause of HIDS remained obscure until
1999. Then, HIDS patients were shown to have mutations in the gene MVK, which codes for
the enzyme mevalonate kinase (MK, EC. 2.7.1.36) (5;6).
MK is an early enzyme in isoprenoid biosynthesis (Fig. 1). This biochemical pathway
produces several compounds, including cholesterol. Deficient MK enzyme activity had been
described previously in a rare autosomal recessive disease, mevalonic aciduria (MA, MIM#
251170) (7). MA is characterized by mild to severe mental retardation, cerebellar atrophy,
manifested by progressive ataxia and dysarthria, myopathy, leading to hypotonia, and
cataracts. Most of these children have dysmorphic facial features. Interestingly, MA patients
suffer frequent inflammatory attacks, with fever, vomiting, diarrhea, arthralgias, cervical
lymphadenopathy and hepatosplenomegaly, during which white blood cell counts and acute
phase reactants are elevated (8) .Hence, despite the differences between MA and HIDS, the
inflammatory crises are similar. The attacks are caused in some way by the MK deficiency,
but it is not yet understood how. Not all patients with periodic fever and elevated
IgD have MK deficiency (9;10). Most of what we know about DPF dates from before the
identification of the molecular defect. Here we will use the term DPF for those patients who
suffer recurrent febrile attacks and have reduced MK activity. The term HIDS then includes
all patients with periodic fever and hyper IgD not explained by infectious or immunological
diseases, irrespective of MK activity.
Epidemiology
At least 170 patients have been diagnosed with HIDS worldwide (11). Most of these are from
Europe, the majority being Dutch (55%) and French (25%), with far smaller numbers being
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reported from Sweden, Germany, the Czech Republic, the United Kingdom, Belgium, Italy,
and Spain. Patients have also been reported from Turkey (12), Japan (13) and the United
States (14). Heightened awareness of the disorder in France and The Netherlands may
partially account for the higher numbers of patients reported from these countries as compared
to neighboring states like Belgium and Germany. Though the exact incidence of HIDS is
unknown, its prevalence in the Netherlands is estimated to be 5 or 6 cases per million total
population. In reality, this figure is probably higher.
Symptoms
Disease onset in HIDS is, characteristically, in infancy. Subsequently, patients
suffer repeated attacks, which can be precipitated by infections, minor trauma,
physical or emotional stress, menses, and by childhood immunizations. Most attacks,
however, occur without any clear precipitating event (3). The duration of the fever attacks can
vary between patients and even from attack to attack in the same patient. In general, fever
lasts for 2 to 7 days, more commonly 3 to 4 days. However, after the normalization of body
temperature, it may take several days to weeks before general well-being is restored. Some
patients with frequent febrile attacks do not recover entirely in-between. The episodes
typically recur without strict periodicity, once every 3 to 6 weeks. However, patients may
experience attacks from once every two weeks to once every 2 years. As patients grow older,
attacks tend to become less severe and less frequent and there may
even be prolonged disease-free intervals.
Fever is the dominant feature of the attacks. Body temperature rises abruptly, often with chills
or rigors, remains high, often over 40°C, and then gradually returns to normal. Immediately
preceding the attacks many patients experience malaise, headache, a sore throat or nasal
congestion; in children irritability and hyperactivity are often noted. During the febrile attacks
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the patients may have various other symptoms (Table I). Abdominal pain, diarrhea and
vomiting are common. The pain is sometimes sufficiently severe to be confused
with that of acute appendicitis. Non-bloody diarrhea is prominent in young children.
Arthralgias accompany fever in most cases. Frank arthritis, mostly affecting the large joints of
the lower extremities, is also common and may persist between crises. Patients frequently
complain of severe headaches (3).
Signs
Tender cervical lymphadenopathy is a constant finding during febrile attacks (3) and the
axillary, inguinal and intra-abdominal lymph nodes may also be swollen. Splenomegaly is
present in nearly half of the patients, though it is a rare finding in adult patients, whereas
hepatomegaly is almost exclusively seen in pediatric
patients.Rashes have been observed in most HIDS cases. These may be macular, maculo-
papular, urticarial, nodular or, rarely, purpuric (15). One Japanese patient has been reported
with erythema elevatum diutinum (13). Oral and genital ulcers occur frequently in HIDS (16)
and in one patient rectal ulcers have been observed (17). Serositis is not a regular feature
of HIDS. However, acute intestinal obstruction due to adhesions has been described in 3
patients, 2 of whom had had no prior surgery (3).
Laboratory findings
Blood abnormalities during attacks are indicative of an acute phase response. Leukocytosis
and granulocytosis are consistent findings; furthermore, the erythrocyte sedimentation rate
and C reactive protein concentration are strongly elevated. In between attacks these values
return to normal (18). Complement levels (C3, C4, CH50) are normal or raised with no
indication of an increased consumption of complement, whereas circulating immune
complexes are present at low levels in 20% of patients (3). About 16% of patients have
microscopic hematuria during attacks, but impairment of renal function is very rare (19).
Introduction
7
Immunological findings
IgD
IgD is a heavily glycosylated immunoglobulin. It comes in two forms, membrane bound and
secreted. Its physiological role is largely unknown, as is its role in the pathogenesis of HIDS
(20). In normal adults, serum IgD concentrations are below 100 IU/ml, but they can rise
during infectious and non-infectious inflammatory diseases (21-23). Pediatric normal values
depend on age. Infants have very little ( <14.1 IU/ml) IgD, whereas normal schoolchildren
may have serum IgD levels as high as 295 IU/ml (24).
Polyclonal elevation of serum IgD is a prerequisite for the diagnosis of HIDS. Hence, all
patients reported have had raised serum IgD at some point in their disease course. There is,
however, no relationship between disease activity and the IgD concentration (2). IgD can even
be entirely normal at times, despite patients having active disease. In young children
symptoms can exist for as long as 3 years before there
is any rise in serum IgD (25). With the recent establishment of normal values for serum IgD
(24) it should be possible to identify HIDS earlier in preschool age children. However, in
older children, there may be considerable overlap between these normal values and those
observed in HIDS patients. With the identification of MK deficiency, it has become possible
to recognize DPF in patients with persistently normal IgD levels. Only one such patient has
been described, but this shows that increased IgD levels are not a prerequisite for the
diagnosis of DPF (5). The high serum IgD level is more likely to be an epiphenomenon than a
cause of the inflammatory state in HIDS, despite indications that IgD may stimulate cytokine
secretion in vitro (26). Furthermore, elevated IgD is not unique for HIDS since it has been
described in patients with other inflammatory conditions, notably the periodic fever aphtous
stomatitis pharyngitis adenitis syndrome (23), familial Mediterranean fever (21;27), Behçet’s
disease (28), bronchiectasis, and immunodeficiency disorders (22), but it is not a consistent
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finding in any of these disorders. The high serum IgD concentration in HIDS is due to
increased production, as evidenced by the high numbers of IgD-containing plasma cells in
bone marrow aspirates (2). The mechanism that leads to this increased synthesis of IgD in
HIDS is unknown.
Other immunoglobulins
Other immunoglobulins are frequently elevated as well. Notably, IgA is raised in up to 93%
of DPF patients, due to a rise in IgA1 (29). Serum IgM can be high as well, but may be normal
or even low. Similarily, serum IgG is usually normal but may be raised, predominantly due to
elevated IgG3 levels.
Cytokines
Cytokine production in HIDS has been studied both in vivo and in vitro, with attention
focused on cytokines, known to induce fever and on mediators with anti-inflammatory
properties. These measurements have been performed in plasma and in supernatants of
cultured leukocytes from HIDS patients.
During febrile attacks the serum levels of interferon-γ and interleukin (IL)-6 rise sharply
(30;31), and tumor necrosis factor (TNF)-α rises to high normal values, whereas IL-1α and
IL-1β are not elevated (30). The effect of the increased stimulation of mononuclear
phagocytes by interferon-γ is reflected in a rise in urinary neopterin excretion simultaneously
with the onset of fever. The neopterin excretion remains high for several days after
normalization of the body temperature (31). Serum levels of the anti-inflammatory mediators
IL-1 receptor antagonist, soluble TNF receptor p55 and soluble TNF receptor p75 are raised
during attacks, whereas IL-10 remains normal (30). The production of many of these
mediators has been studied in vitro. In supernatants of unstimulated cultures of whole blood
samples, obtained during attacks, IL-1β is not increased (30). Culture supernatants of
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peripheral blood mononuclear cells (MNC) obtained between attacks, however, contained
high concentrations of IL-1β which increased even further upon stimulation with LPS (32)
Although plasma levels of TNFα stay within normal limits, its concentration is increased in
the supernatants of unstimulated cultures of whole blood samples drawn between attacks.
When stimulated with LPS, the supernatants of such cultures showed an elevated TNFα level,
which was even higher when the blood cells had been obtained during an attack (30). Similar
results were obtained in culture supernatants of isolated MNC obtained between attacks (32).
Notably, spontaneous IL-1β, IL-6 and TNFα production by isolated MNC is elevated in HIDS
and rises further on stimulation with LPS. Taken together these data are compatible with
macrophage activation during the febrile attacks. Between the febrile attacks the in vitro
findings are still compatible with an increased activity of the mononuclear phagocytic
compartment. The cause of this macrophage activation is unknown. While activated Thelper-1
cells are known to induce macrophage activation, the high IgD and IgA levels are more
compatible with an increased activity of Thelper-2 cells (33). However, direct evidence of T-
cell activation during attacks is lacking.
Biochemistry
The identification of MK deficiency as the cause of DPF links this syndrome to mevalonic
aciduria. This latter inborn error was first described by Berger et al. in 1985 (34) and
subsequently recognized to be caused by a deficiency of MK enzyme activity (7). In MA the
MK enzyme activity is usually virtually absent when measured in cultured skin fibroblasts or
lymphoblasts of patients (<4% of the control mean, usually<0.5%)(8;35). In DPF, however, a
residual MK activity varying between 1 and 8% can be measured both in fibroblasts and
leukocytes from patients (5;36). As a result of the MK deficiency, excretion of mevalonic acid
in urine occurs, although the levels of excreted mevalonic acid vary significantly between
both syndromes. MA is characterized by a massive and constitutive excretion (1000-56000
Introduction
10
mmol/mol creatinine) (8), while in DPF the mevalonic acid excretion is moderate (4-28
mmol/mol creatinine) and may be normal between febrile crises (5) In healthy controls, the
excretion of mevalonic acid in urine is usually less than 1 mmol/mol creatinine.
MK is the first enzyme to follow 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA
reductase) in the mevalonate pathway and converts mevalonate into 5-phosphomevalonate
(Fig. 1). The mevalonate pathway provides cells with isoprenoids that are essential for diverse
cellular processes. The main end products include ubiquinone-10 and haem A, both of which
are necessary for electron transport, isopentenyl tRNA (involved in protein translation),
dolichol (essential for N-linked protein glycosylation), and the farnesyl and geranylgeranyl
groups used for isoprenylation of the proteins involved in cell proliferation and
differentiation. In addition to these non-sterol isoprenoids the mevalonate pathway produces
cholesterol, a structural component of cellular membranes and precursor for bile acids and
steroid hormones (37). HMG-CoA reductase, which converts HMG-CoA into mevalonate,
catalyzes the main rate-limiting step in isoprenoid biosynthesis and is among the most tightly
regulated enzymes in nature (37). Indeed the statins, which are drugs widely used to treat
atherosclerosis and familial hypercholesterolaemia, are potent competitive inhibitors of the
reductase; they block the synthesis of mevalonate and as a consequence lower the endogenous
synthesis of cholesterol. The use of statins can trigger adaptive reactions yielding up to 200-
fold increased HMG-CoA reductase activity. A therapeutic trial in which two MA patients
were treated with low doses of lovastatin in order to block mevalonate production, however,
was unsuccessful and had to be abandoned because of the development of severe clinical
crises (8).
Several metabolic diseases have been described which are caused by defects in the isoprenoid
pathway. Five disorders, Smith-Lemli-Opitz syndrome (38-40), desmosterolosis (41), CHILD
syndrome (42), Greenberg dysplasia (43) and X-linked dominant chondrodysplasia punctata
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(44;45)only affect the sterol biosynthesis. MA and DPF affect the biosynthesis of all
isoprenoids. Periodic fevers and dysregulation of the immune system are only present in DPF
and MA, which indicate that a shortage of cholesterol is not the pathogenetic basis of the
periodic fevers. This is also supported by the observation that cholesterol levels are usually
(near) normal in patients with MA (8). Furthermore, the incorporation of radiolabeled acetyl-
CoA into cholesterol by cultured skin fibroblasts of DPF and MA patients appears to be
comparable with that in controls (7).The differences in mevalonate excretion between DPF
and MA could be caused by a difference in the regulation of HMG-CoA reductase activity. In
MA there may be a constitutive induction of HMG-CoA reductase, as suggested by the
elevated reductase activity in fibroblasts from MA patients and the levels (7) of excreted
mevalonate (> 800 mmol/ day) which greatly exceed the level of normal whole body
cholestrol biosynthesis (4 mmol/day, equivalent to 24 mmol of mevalonate/day) (8), while in
DPF the reductase activity appears only to be raised during fever episodes(46)
Molecular biology
The cause of DPF was independently identified in 1999 by a Dutch research group and
Dutch/French consortium using two different approaches. Both groups ended up with the
same gene, MVK, coding for the enzyme MK. Houten et al. (5) performed organic acid
analysis of urine from one periodic fever patient during
an episode of fever and found elevated levels of mevalonic acid. This patient had all the
characteristics of HIDS except for an elevated IgD. Subsequent organic acid analysis in 2
HIDS patients, however, also revealed elevated levels of mevalonic acid during episodes of
fever. The elevated levels of mevalonic acid in urine suggested a defect in the metabolism of
mevalonate, and enzyme measurements revealed a profound deficiency of MK enzyme
activity. Subsequent mutation analysis revealed several disease-causing mutations in the
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MVK gene. Drenth et al. performed linkage analysis and obtained linkage at chromosome 12
position q24 (6). After narrowing the region to 9 cM, they concluded that MVK was a good
candidate gene and subsequently identified mutations in this gene in several HIDS
patients.Since the human MVK cDNA sequence had already been cloned, both groups
performed mutation analysis at the cDNA level. This revealed a common missense mutation,
a G > A transition at nucleotide 1129 changing the valine at position 377 into a isoleucine
(V377I), in 32 out of 38 HIDS patients (10;36;47). Most patients were compound
heterozygotes for this mutation. Two additional missense mutation were commonly identified.
an A > C transversion at nucleotide 59 and a T > C transition at nucleotide 803, which change
the histidine at position 20 into a proline (H20P) and the isoleucine at position 268 into a
threonine (I268T), respectively. Since the latter two mutations were also identified in MA
patients (35;48), this strongly suggested that the V377I mutation is responsible for the DPF
phenotype of MK deficiency. Indeed, thus far only 6 patients have been described without this
mutation (10;36). One of these was compound heterozygous for a C > T transition at
nucleotide 500, changing the proline at position 167 into a leucine (P167L). The other allele
carried the I268T mutation, which was also found in MA patients, suggesting that the P165L
mutation is responsible for the DPF phenotype in this patient.
The MVK gene was previously reported to be a single copy gene located on chromosome
12 postion q24 (49;50), which is in accordance with the linkage analysis performed by Drenth
et al. (6). We have recently resolved the genomic organization
of the mevalonate kinase gene, showing it to consist of 11 exons (36). Figure 2 is a schematic
representation of the MVK gene and includes all the mutations currently identified in both MA
and Dutch type periodic fever.
In order to study the effect of the identified missense mutations on MK activity, most of the
mutant proteins have been characterized by immunoblotting and heterologous expression. The
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first identified mutation in MA, N301T, was expressed in COS-7 cells and showed a
markedly decreased enzyme activity varying between 5 and 20% of the activity of wild type
MK (49). More recently, a mutation in MA was characterized, which changed the affinity of
the enzyme for its substrate mevalonate when expressed as a recombinant fusion protein in
Escherichia coli (A334T) (51). The V377I mutation had considerable residual activity when
expressed in E. coli (35% compared to the control), but MK protein in fibroblast lysates of
HIDS patients was hardly detectable, as shown by immunoblotting with an MK-specific
antibody. This indicates that, although this mutation has some effect on enzyme activity, it
predominantly affects the stability of the MK protein in vivo. (5). All of the other
characterized mutations result in MK proteins with markedly decreased enzyme activity when
expressed in E. coli and/or decreased protein levels in fibroblast lysates (H20P, T243I,
L264F, L265P, I268T and V310M) (35;48).TRIC REVIEW Periodic fever and mevalonate
kinase deficiency / J. Frenkel et al.
Differential diagnosis
DPF should be distinguished from a number of hereditary and non-hereditary disorders with
which it has features in common. First, infectious diseases and cyclic neutropenia should be
ruled out. Systemic onset juvenile chronic arthriis, like DPF, is characterized by fevers,
transient rashes, lymphadenopathy, hepatosplenomegaly, and arthritis. However, the onset is
rarely in the first year of life, the fever has a spiking pattern, the disease flares usually last
many weeks instead of days, and the arthritis is destructive. Contrary to DPF, serositis is
common and diarrhea is usually absent. Furthermore, there is no ethnic predisposition and the
disease is not familial in occurrence. Familial Mediterranean fever typically occurs in patients
of Turkish, Armenian, Iraqi or Sephardic Jewish ancestry. It is characterized by recurrent
bouts of high fever, accompanied by arthritis and by severe abdominal pain due to serositis.
Patients may have pleuritis, pericarditis, acute scrotal pain or an erysipelas-like rash of the
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lower part of the legs (52-54). The onset of attacks is usually at a slightly later age (2-10
years) than in HIDS and the attacks typically last only 12-72 hours (55). Diarrhea, headache,
generalized rashes, lymphadenopathy and hepatosplenomegaly do not feature in FMF.
Amyloidosis is a common serious late complication of FMF, which may lead to nephrotic
syndrome and renal failure. In contrast to DPF, the attacks of FMF can be largely prevented
by colchicines (56). This treatment reduces the future development of amyloidosis.
Inheritance is autosomal recessive and the responsible gene, MEFV, on chromosome 16p13.3
codes for a protein of unknown function called pyrin or marenostrin (57;58). Molecular
diagnosis is feasible in most FMF patients, but in at least 20% of patients one or both alleles
appear normal (53;59-62). FMF therefore remains primarily a clinical diagnosis (63)
The TNF-receptor associated periodic syndrome (TRAPS) is a rare disorder that has been
encountered primarily in Irish and British families and was therefore called familial hibernian
fever, but it has also been encountered in families from other countries, including France,
Finland, Israel, and The Netherlands. The onset of this disease is between 2 and 20 years of
age, after which febrile attacks recur at irregular intervals, typically 2 to 4 times every year
(64). The duration of fever varies from some days to many weeks. The fever may be
accompanied by edema of the eyelids, conjunctivitis, myalgias, painful erythema of the arms
and legs, arthralgias, and scrotal and abdominal pain. As in FMF, these patients may have
serositis, and some have developed amyloidosis. In contrast to DPF, lymphadenopathy is
absent. Inheritance is autosomal dominant and molecular diagnosis has become possible with
the identification of the affected gene, TNFR1A. This gene encodes the 55kDa TNF receptor
protein (65) and mutations affect the extracellular domain of this receptor, interfering with
receptor shedding.
Familial Cold-induced Autoinflammatory syndromeand Muckle Wells syndrome.
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These two rare syndromes with autosomal dominant inheritance were shown in 2001 to be
due to mutations in the same gene. This gene, CIAS1, encodes cryopyin, a protein related to
pyrin / marenostrin (66). Affected patients have recurrent short-lived (<24 hours) episodes of
fever and urticariform rash from infancy. Cojunctivitis and arthralgias are (67) often present
during the attacks. Attacks triggered by exposure to cold define the clinical phenotype of
cold-induced autoinflammatory syndrome, whereas perceptive deafness and amyloidosis
characterize the Muckle-Wells syndrome. In fact, there is overlap between these phenotypes,
even within affected families (68).
The CINCA syndrome, which stands for Chronic Infantile neurologic cutaneous and articular
syndrome is also known as Neonatal onset multi-system inflammatory disease (NOMID)
(1;69;70).It is a sporadically occurring inflammatory disease with recurrent short fever bouts,
non-pruritic urticara, deforming arthropathy. Neurological involvement consists of aseptic
meningitis, intracranial hypertension and cerebral atrophy ad is reflected in headache, varying
degrees of developmental delay, focal deficits and seizures. Patients often fail to thrive and
remain short statured. Uveitis and papillitis optica may lead to blindness. Peceptive deafness
is a common sequel. Dysmorphic features, such as frontal bossing and saddle nose, develop
gradually. CINCA is a clinical diagnosis.
The periodic fever aphtous stomatitis, pharyngitis and adenopathy (PFAPA) syndrome is
characterized by febrile attacks that last 2-8 days and recur every 2-8 weeks (23;71;72). The
fever is accompanied by aphthous stomatitis, cervical lymphadenopathy and pharyngitis, but
some patients also experience headache, abdominal pain, diarrhea or rashes. IgD may be
mildly elevated. Hence, differentiation from HIDS can be particularly difficult. The PFAPA
syndrome is, however not familial in occurrence (23;72).
Although the majority of patients initially classified as HIDS were MK deficient when tested,
about 25% of patients were found to have normal MK activity. These children tend to have a
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later age of disease onset, but could not otherwise be distinguished from DPF cases (9). These
patients have been said to have variant HIDS (73). Ultimately, the correct diagnosis of HIDS
sensu strictu, i.e. DPF, can only be made by the demonstration of a reduced MK activity in
cultured skin fibroblasts or mononuclear cells or by the demonstration of mutations in both
alleles of the MVK-gene.
There is no uniform, evidence based diagnostic approach for children with recurrent fever.
The overlapping clinical presentations defy a straightforward decision tree. Rather, the
combination of clinical and epidemiological features in a given patient makes certain
diagnosis less or more probable. In table 2 such features of the various periodic fever
disorders are set side by side. The probability for a given feature to point to a specific
diagnosis is, however, qualitative at best. To enable a more quantitative approach, prospective
studies are needed in children, who present with recurrent fever of unknown origin,. A
European working party (www.pres.org.uk) is currently addressing this question.
Treatment
Most therapeutic interventions in HIDS have not been systematically studied. Non-steroidal
anti-inflammatory drugs, colchicine, intravenous immunoglobulins, and cyclosporin A have
been tried in some patients and were, in most cases, found to be ineffective. Some patients
responded favorably to corticosteroids. The long-term use of corticosteroids in childhood has
too many side effects, however, to justify their use as maintenance treatment to prevent
attacks. Thalidomide was tested in a double-blind placebo-controlled trial (74). There was no
significant clinical benfit.
Prognosis
The frequency and the severity of attacks appear to decrease with age. In our experience,
however, all children with DPF have remained symptomatic. In contrast, children with variant
HIDS, i.e. recurrent fever and elevated serum IgD but normal MK activity, were likely to
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enter long-term remission. There are some indications that pregnancy may further decrease
disease activity (75). Some patients have long-term sequelae, however. Three patients
developed peritoneal adhesions, possibly as a consequence of serositis. One child, diagnosed
with HIDS, developed end stage renal failure due to crescentic glomerulonephritis (76).That
patient was, however, later shown to have MA (19). This shows the two disorders are really
part of a continuous spectrum of mevalonate kinase deficiency. Joint damage has not been
reported in HIDS.
Among the patients in the HIDS registry two deaths have been reported, one by suicide and
one from a stroke (3). It is doubtful whether these complications are related to HIDS. Though
HIDS may cause little excess mortality or permanent organ damage, the impact of a disease
that causes patients to miss school frequently from kindergarden through high school cannot
be underestimated. Data on the psychosocial effects are lacking, however.
Future directions
The identification of the molecular defect in DPF will have implications for our understanding
of the disease, its pathogenesis, its natural history and its treatment. Efforts are underway to
elucidate the pathophysiological mechanisms by which mevalonate kinase deficiency leads to
periodic fever. Other defects in the isoprenoid pathway with similar clinical effects might be
expected, but these have not yet been identified.
With a definitive diagnostic criterion at hand, the patient population is better defined, which
will enable us to reappraise the clinical presentation and the natural course of the disease.
Finally, we are now in a position to assess prospectively the effect of interventions
in a circumscript patient group. The involvement of the isoprenoid pathway in the
pathogenesis suggests that treatment with statins, which interfere in the earliest step of this
route, might be beneficial. A clinical trial with such a compound is underway in adults
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(11).Results of both mechanistic studies and intervention trials should ultimately shed light on
the physiological role of isoprenoid metabolism in inflammation
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Table I. Cumulative incidence of symptoms and signs during febrile attacks in HIDS
(modified from reference 3).
Fever 100% Lymphadenopathy 94%
Chills 76% Skin rash 82%
Abdominal pain 72% Splenomegaly 48%
Diarrhea 82% Serositis 6%
Vomiting 56% Arthritis 68%
Headache 52%
Arthralgias 80%
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Table 2: Comparison of Childhood Autoinflammatory Diseases
FMF HIDS (DPF) TRAPS FCAS / MWS CINCA Systemic JIA PFAPA
Inheritance AR AR AD AD Unknown None None
Gene MEF-V MVK TNFRSF1A CIASI
Protein Myrenostrin
(Pyrin)
Mevalonate
Kinase
TNFRSF1A Cryopyrin
Function Unknown Isoprenoid
biosynthesis
TNF receptor Unknown
Usual
ethnic
origin
Jews, Arabs,
Turks,
Armenians
Dutch,
French,
Other
British, Irish,
Other
European Worlwide Worldwide Worldwide
Usual onset
age
Childhood Infancy Variable Neonatal or
infancy
Neonatal Childhood Pre-school
Duration of
Attacks
12 – 72 hrs 3 – 5 days Days to weeks < 24 hrs Several
hours
Weeks 3 – 6 weeks
Interval
between
attacks
Weeks to
Months
Weeks to
Months
Weeks to
months
Variable Days Weeks or
none
3 – 6 weeks
Vomiting + +
Diarrhea + + +
Abdominal
pain
++ + + + +
Peritonitis ++ + +
Pleuritis + ++ +
Scrotal pain Infrequent ++
Rashes Erisipelas-
like (rare)
++ (Various) ++ Migratory
tender
erythematous
plaques
++Urticaria ++ Non-
pruritic
urticaria
++ Evanescent
pink macules
Eye disease ++
conjunctivitis,
periorbital
oedema
Conjunctivitis Papillitis,
uveitis
Hearing MWS:
deafness
Perceptive
deafness
Mucosal
Involvement
Aphthous
ulcers
++ Aphthous
ulcers,
pharyngitis
Joint
Involvement
Monoarthritis Arthralgias,
oligoarthritis
Arthralgias Arthralgias Destructive
arthritis of
large joints
Destructive
Polyarthritis
Arthralgias
(rare)
Headache + ++ + + +
Myalgias Infrequent Infrequent ++ + +
Lymphaden
opathy
++ + + + ++
Splenomeg
aly
+ + + +
Amyloidosi
s
+ + FCAS +
MWS ++
+ +
Helpful
tests
Response to
colchicine
Elevated
serum IgD,
IgA,
mevalonic
aciduria acid
Serum soluble
TNFRSF1A
CSF
Pleiocytosis
Diagnostic
confirmatio
n
MEFV gene
analysis
MVK gene
analysis
TNFRSF1A
gene analysis
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Fig. 1. Isoprenoid biosynthesis. Mevalonate kinase catalyzes the reaction immediately after
HMG-CoA reductase. End products of this route include isopentenyl tRNAs, dolichol, Heme
A, ubiquinone, farnesyl and geranylgeranyl groups for protein isoprenylation, and cholesterol,
with all its derivatives. In mevalonate kinase deficiency there is accumulation of mevalonic
acid.
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Fig. 2. Schematic representation of the organization of the MVK gene. The locations of all the
mutations identified at present in Dutch type periodic fever and mevalonic aciduria are
indicated.
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Abstract
Objectives
The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) was recently found to
be caused by a deficiency of mevalonate kinase (MK). The aim of this study was to examine,
whether a relationship exists between the clinical expression of HIDS and the extent of MK
deficiency.
Methods
Medical records of children diagnosed with HIDS were reviewed for clinical features and
serum immunoglobulin values. The mevalonic acid excretion in urine and the enzyme activity
of MK in patient’s cells were measured and the MVK cDNA’s sequenced
Results
Fifteen patients with recurrent fever and raised serum IgD were included. Their clinical
features varied. Eleven patients had a deficiency of MK, caused by mutations in the MVK
gene. One mutation (V377I) was common to all eleven patients. Nine patients were
compound heterozygous for V377I and various other MVK mutations. There was no apparent
relation between the observed mutations and the clinical features. Surprisingly, four boys had
normal MK activity and no MVK mutations
Conclusions
Most HIDS patients have mutations in the MVK gene. The clinical variability observed can
not be explained by genotypic differences. Periodic fever and elevated IgD can result from
other, still unknown causes. Hence testing for MK deficiency is necessary in patients with
unexplained periodic fever.
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Abbreviations
HIDS  Hyper IgD Syndrome
MK Mevalonate kinase
MNC  Mononuclear cells
MVK Gene encoding mevalonate kinase
FMF Familial Mediterranean Fever
PFAPA Periodic Fever Aphtous Stomatitis Pharyngitis Adenitis
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Introduction
The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), also known as Dutch
type periodic fever (MIM#260920), is an autosomal recessive disorder, characterised by
febrile attacks recurring at more or less regular intervals and the presence of an elevated
serum IgD concentration (>100 IU/ml) (1). Clinical features of the febrile attacks include
cervical lymphadenopathy, splenomegaly, hepatomegaly, skin rash, vomiting, diarrhoea,
arthralgias, and arthritis. Patients often complain of malaise, chills, headache, nausea or
abdominal pain (2). The diagnosis of HIDS has always been based on the occurrence of both
recurrent unexplained fever and elevated serum IgD levels. Recently, we and others identified
the underlying genetic defect of the syndrome, namely mutations in the gene MVK, which
lead to a deficiency of the enzyme mevalonate kinase (3;4). MK catalyses the
phosphorylation of mevalonic acid into 5-phosphomevalonate. It is the enzyme immediately
following 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase in the isoprenoid
biosynthesis pathway. This pathway produces cholesterol and numerous non-sterol
isoprenoids, involved in a large variety of cellular processes (5). In HIDS, the deficiency of
MK becomes evident during febrile attacks, when its substrate, mevalonic acid, accumulates
in plasma and is excreted in the urine. Although it is known that febrile episodes in HIDS can
be triggered by injuries, infections, or vaccinations, it is unclear how these exogenous factors
interact with the endogenous biochemical defect to give rise to the inflammatory episodes. So
far, 9 cases of HIDS have been published in whom MK activity had been determined (3;4).
All were found to have a markedly reduced MK enzyme activity. Here, we describe our
findings in a group of 15 children with HIDS, including 4 who have been previously
described (2;3). Surprisingly, in 4 children normal MK activity was found. These cases will
be described in more detail.
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Patients and methods
We included in this study all children with HIDS, who had been visiting the 3 participating
children’s hospitals between January 1997 and October 1999. The diagnosis of HIDS was
based on the following criteria: 1) recurrent fever over 38.5°C, not explained by infections or
otherwise and 2) a serum-IgD >100 IU/ml established at least once, preferably on 2 occasions
at least 1 month apart. Throughout the text patients are identified by their entry number in the
international Hyper IgD study group registry (2). Four patients (numbers 26, 50, 132, and
139) have been described previously (2;3).
After approval by the medical ethical committee and informed consent by parents, patient
charts were reviewed for clinical characteristics, disease history, and serum immunoglobulin
levels.
MK activity was determined in peripheral blood MNC using 14C-labelled mevalonate as
substrate (6)speidel and expressed as the percentage of the average MK activity, determined
simultaneously in MNC from healthy control subjects. Normal values are 166.3 ± 69.1
nmol/min.mg.
Urine samples were collected during febrile crises, not due to intercurrent infection.
Mevalonic acid was measured in, by stable isotope dilution gas chromatography mass
spectroscopy of the trimethylsilyl ether / esters using 2H7 –mevalonolactone as an internal
standard (7).
In all patients, mutation analysis of the MVK cDNA was performed as described previously
(8). Briefly, cDNA was prepared from total RNA isolated from MNC. Two sets of MVK-
specific primers with –21M13 or M13rev extensions were used to amplify MVK cDNA in 2
overlapping fragments by PCR. Both PCR fragments were sequenced in both directions using
Frenkel. Variability in Hyper IgD syndrome
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fluorescent primers on an ABI 377A DNA sequencer (Perkin-Elmer), according to the
manufacturer's instructions.
Results
Clinical heterogeneity
The demographic data and disease courses of the 15 patients are summarised in table 1. Of the
15 patients 5 were girls and 10 were boys. Age ranged from 2 to 20 years with a mean age of
9.4 years. One patient (No 138) was of Turkish descent, whereas the remaining 14 patients
were of Dutch origin. There was no consanguinity in any of the families and there were no
additional family members affected. The febrile attacks started between 2 months and 14
years of age, with a median of 6 months. On average, the fevers lasted for 4.2 days and
recurred every 3 to 7 weeks. In individual patients, however, the duration of the febrile
episodes varied considerably. Similarly, the interval between attacks varied during the disease
course from less than 2 weeks up to many months. In fact, 2 children (No 50 and 138) had
been free of symptoms for over 12 months.
Table 1 summarises the clinical features accompanying the febrile crises. All children had
fevers up to 40°C, accompanied by malaise and fatigue. In many instances, fever was elicited
by mental stress, strenuous exercise or infections. Pharyngitis was documented in 8 patients,
pneumonia in 7, Otitis in 5, but there were no recurrent severe infections in any patient.
Childhood vaccinations were followed by fever in the majority of patients. However, most
attacks came apparently unprovoked.
Usually there were prodroma such as fatigue, anorexia or behavioural changes. Onset of fever
was brisk, with 40% of patients experiencing chills. One patient (No139) suffered repeated
febrile seizures. Temperature normalised after 3 to 7 days of high fever. Subsequently, most
patients remained listless and tired for another 3 to 7 days.
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The rashes that were reported in 11 of 15 patients varied from faint erythema to
maculopapular and urticarial exanthemata. One patient had recurrent swelling of hands and
feet during attacks, another had so only once. Of the 15 patients, 11 reported headache during
attacks. Abdominal pain was very common, often accompanied by diarrhoea and/or vomiting.
Arthralgias were present in 80% of patients, whereas arthritis, defined as painful swelling of
joints was rare. Lymphadenopathy, hepatomegaly, and splenomegaly were present in the
majority of patients. Notably, there was no recurrent pharyngitis or aphtous stomatitis in any
patient.
Growth was normal in all children, but 2 patients had very mild developmental delay and 1
patient (No136) was severely mentally retarded . He died at the age of 17 years.
Biochemical and molecular heterogeneity
Serum IgD levels were raised above the upper limit of normal (100 IU/ml) at least once in all
15 children and on more than one occasion in 14. Serum levels of IgG, A, and M were
repeatedly raised in most patients (table2).
Eleven of 15 patients were found to have a deficient mevalonate kinase activity in peripheral
blood MNC (1–7%, normal 100 ± 42%), In 9 of these 11 patients urine was obtained during
fever. Urinary mevalonic acid concentration, normally below 1 mmol/mol creatinine, was
elevated in all 9 samples (4.8 - 41.5, average 17.5 mmol/mol creatinine), whereas it was not
elevated in the three living patients with normal MK activity.
In all 11 patients with reduced MK activity mutations could be identified in the MVK cDNA.
The observed mutations and their consequent amino acid changes are represented in table 3.
All MK deficient patients carried the substitution of the guanine at position 1129 by an
adenine (1129G→A), leading to an amino acid change from valine to isoleucine at position
377 (V377I). Two patients were homozygous for this mutation at the cDNA level, confirmed
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by sequencing of the parental cDNA’s. All other patients were compound heterozygous for 2
mutations (table 3).
Clinical features appear unrelated to molecular variability
We found no clear relation between the different genotypes and residual MK activity. Neither
the genotype nor the degree of enzyme deficiency correlated with the clinical severity of the
disease. In 4 male patients a normal MK activity was found (No’s 50,138, 141, and 143).
These boys will be described in more detail below.
Normal MK activity in four patients
Case No 50: This 8-year old Dutch boy had suffered repeated bouts of fever from the age of 5
weeks. Fever started abruptly and remained high for 2 to 5 days, recurring every 2 to 3 weeks.
Episodes were often triggered by minor infections. General malaise and painful cervical
lymphadenopathy accompanied the attacks. On occasions he suffered from a sore throat. He
had no rash, oral ulcers, arthralgias, headache, abdominal pain, diarrhoea or vomiting during
attacks. Once, mild hepatomegaly, without splenomegaly, was noted.
During attacks, there was leukocytosis (14.1-16.7x10 9/l) with granulocytosis and band forms.
Paracetamol reduced the temperature, but non-steroidal anti-inflammatory agents were
ineffective in preventing attacks.
Case No 136: This 17-year old Dutch boy was born small for date (2250g) after a full term
pregnancy. He was noted to have hypotelorism, antimongoloid, slanting short palpebral
fissures, low-set ears, high arched palate, dental crowding, and clinodactyly of the fifth
fingers. His psychomotor development was severely delayed. No syndromal diagnosis had
been made, despite full metabolic and cytogenetic workup.
From the age of 4 years, he had suffered repeated attacks of diarrhoea.
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Recurrent bouts of fever started at the age of 14 years. The fever was sudden in onset,
remained around 40°C for 3 to 7 days and recurred monthly without strict periodicity. There
were no evident triggers for the attacks.
The episodes were accompanied by fatigue, anorexia, abdominal pain, diarrhoea, and
vomiting. He experienced arthralgias and later in the disease course, he had painful swellings
of metacarpophalangeal and proximal interphalangeal joints. Rash, lymphadenopathy,
hepatosplenomegaly had been absent. Serositis was suspected, since he suffered intestinal
obstruction due to adhesions, without prior abdominal surgery. During attacks, he had
leukocytosis with granulocytosis and band forms, and an elevated sedimentation rate and C-
reactive protein. IgG, A, M, and D were elevated (table 2). Antibiotic treatment was
ineffective and only long-term treatment with tolmetine and prednisolone could reduce, but
not abort, symptoms.
At the age of 17 years, he died from the complications of a perforated gastric ulcer. At
autopsy the gastric perforation and peritonitis were confirmed. An unexpected finding was a
sterile pericarditis, further supporting the presence of polyserositis.
Case No 138: This 8-year Turkish boy had developed febrile reactions after childhood
vaccinations but had otherwise been well during the first years of life. He suffered repeated
bouts of fever from the age of 3½ until the age of 7 years. His fever recurred every 4 weeks.
Onset was abrupt, but without chills. His fever was spiking and lasted 4 to 7 days, before
resolving spontaneously. Accompanying symptoms were headache, anorexia, general malaise,
abdominal pain and diarrhoea. Examination during attacks revealed cervical
lymphadenopathy and hepatosplenomegaly, but no recurrent pharyngitis, uveitis, oral or
genital ulcers. He had recurrent otitis media and streptococcal pharyngitis once, but most
febrile episodes were without any recognisable infectious focus. There were no other affected
family members.
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Immunoglobulins were repeatedly elevated. Notably, IgD was persistently raised (231-415
IU/ml), despite clinical remission. Sequence analysis of the MEFV-gene was normal,
rendering Familial Mediterranean Fever (FMF) unlikely and Behçet’s syndrome was
excluded on clinical grounds.
Case No 140: This 6 year-old Dutch boy had suffered repeated febrile attacks from the age of
3 months. Attacks were triggered by vaccinations and infections, but usually came
unexpectedly, starting with chills and peripheral cyanosis followed by an sudden rise in
temperature up to 41.4°C. Fever remained high during 3 to 5 days and recurred every 3 to 5
weeks. Over the last 12 months, his fever had not exceeded 38,5°C and attacks came 2 to 3
months apart. Fatigue and anorexia preceded the attacks. The crises were accompanied by
abdominal pain, headache, vomiting, and cervical lymphadenopathy, but not by joint pains,
rash, hepatosplenomegaly, oral ulcers, or pharyngitis. Once the fever had abated, the boy
remained tired and listless for about 3 more days. Serum-IgG had ranged between 9.7 and
12.6 g/l, IgM between 0.8 and 2.2 g/l and IgA between 0.8 and 1.25 g/l. Serum-IgD was
persistently elevated between 157 and 180 IU/ml. During attacks leukocytes, granulocytes,
sedimentation rate and C-reactive protein were raised.
Apart from oral antibiotics, which seemed ineffective, no other medications had been tried.
In all 4 boys, the family history was negative for recurrent fever, making the autosomal
dominant TNF-receptor associated periodic syndrome very unlikely. In three, the ethnic
background did not suggest Familial Mediterranean Fever. Cyclic neutropenia was formally
ruled out in all 4 and the PFAPA syndrome and systemic onset juvenile idiopathic arthritis
were ruled out on clinical grounds. During most of the attacks, no infectious focus could be
identified.
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Discussion
Periodic fever in childhood is not uncommon. Currently, various clinical syndromes,
characterised by periodic fever can be distinguished. These include the autosomal recessive
syndromes HIDS and Familial Mediterranean Fever, the autosomal dominant TNF-Receptor
Associated Periodic Syndrome (TRAPS), and the non-hereditary disorders Periodic Fever,
Aphtous stomatitis, Pharyngitis, Adenitis (PFAPA) syndrome (9;10), and systemic onset
juvenile idiopathic arthritis.
In the past these syndromes could only be diagnosed on the basis of clinical criteria. Recently,
however, the molecular defects in HIDS (3;4), FMF (11;12), and TRAPS (13) have been
identified. This knowledge now helps us to differentiate these disorders from each other and
will provide better insight in the pathogenetic mechanisms involved in the various periodic
fever syndromes.
The clinical presentation of most periodic fever syndromes shows considerable inter-
individual variation. With the identification of the molecular defects, the question, whether
this clinical heterogeneity reflects an underlying genetic heterogeneity, can be addressed. We
investigated a group patients, originally diagnosed with HIDS by the occurrence of episodic
fever in combination with an elevated serum IgD after the exclusion of other (infectious)
causes for the fever. As we now know, HIDS is due to a deficiency of mevalonate kinase
(MK), an enzyme involved in one of the early steps of isoprenoid biosynthesis. This
biochemical pathway yields many substances, including cholesterol, dolichol, heme A,
ubiquinone, and hydrophobic moieties for posttranslational protein modification (farnesyl-
and geranyl-geranyl-groups). It is unknown how MK deficiency leads to recurrent febrile
episodes. Our previous work has shown that MK deficiency can also give rise to periodic
fever without raised IgD (3). Hence, in patients with unexplained periodic fever, MK activity
should be determined irrespective of serum IgD.
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To examine, whether our clinically diagnosed HIDS patients indeed had MK deficiency, we
measured MK enzyme activity in all 15. MK was deficient in 11 patients. Urinary mevalonic
acid excretion in HIDS is known to rise during fever, but it is not known whether MK activity
can be adversely affected by influences such as fever or mental stress. Hence, enzyme activity
measurements were performed only on blood, drawn between fever episodes. In the 11 MK
deficient patients we found mutations in both alleles of MVK, the gene encoding MK. At the
molecular level there was heterogeneity among the MK-deficient patients. All patients carried
the V377I allele, which has previously been shown to lead to an unstable protein with reduced
enzymatic activity (3). Two patients were homozygous for the V377I allele. The other
patients were compound heterozygous for this allele and 1 of 4 other mutant alleles. Two of
these, 59 A→C and 803T→C, are known not to produce an enzymatically functional protein
(3). Patients homozygous for mutations that completely abolish MK activity are known to
present with a distinct clinical syndrome, called mevalonic aciduria (MA). MA is
characterised by mental retardation, facial dysmorphy, and failure to thrive, in addition to
febrile crises (14). Apparently the V377I allele is responsible for the milder phenotype of
HIDS as compared to classical mevalonic aciduria. The mutations 1162 C→T and 404 T→C
had not been previously described in HIDS or MA. The predicted effect of the mutation 1162
C→T is a truncation of the protein at position 388. The functional effect of the S135L
substitution, resulting from the mutation 404 T→C, is unknown. However, it is likely to lead
to loss of function, since the serine residue at position 135 is highly conserved among
mammalian species and the measured MK activity in the patient was only 1% of normal. A
genotype phenotype relation exists within the broad spectrum of mevalonate kinase
deficiency in that severe mutations leading to virtually abolished MK activity give rise to the
MA phenotype, whereas mild changes lead to the HIDS phenotype. In contrast to findings in
MA, none of the patients described here had less than 1% residual enzyme activity. Among
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these, we could not establish a relation between the different mutations and residual MK
activity. Neither could we relate the severity of clinical symptoms to the residual activity of
MK. For example, 4 patients are compound heterozygous for I268T and V377I. Yet, the
residual MK activity varies from 2% in patient 132 to 7% in patient 135. These 2 patients are
both severely affected. On the other hand, patient no 137 is only mildly affected, although her
residual MK activity is intermediate between that of patients No 132 and 135.
Interestingly, of the 15 children originally diagnosed with HIDS, 4 showed a normal MK
activity, indicating that HIDS is a genetically heterogeneous disorder. These patients had been
diagnosed as HIDS because of elevated IgD and recurrent fever. In 2 patients, however, the
febrile episodes had been absent for more than 18 months. Although this is not uncommon in
HIDS, it sets these cases apart from the MK-deficient patients in this report. Indeed, the
symptoms of these 4 patients, all boys, differed slightly from our MK-deficient patients. The
diagnosis of HIDS could not have been rejected on clinical grounds, however. The clinical
phenotype reported in HIDS patients before MK testing became available (2) and in our MK-
deficient patients is not uniform and the clinical spectrum of HIDS accommodates all the
characteristics of these 4 boys.
In 2 patients with normal MK activity the onset of disease was beyond 3 years of age. In
contrast, all MK deficient patients described here and 70.% of reported HIDS cases (2) had
their onset of disease in the first year of life. Another difference was the absence of vomiting,
arthralgias, and rash in 3 of 4 patients with normal MK activity, while these features were
present in the majority of the MK deficient patients as well as in most reported HIDS patients.
Therefore, although not obligatory in MK deficiency, the absence of absence of vomiting,
arthralgias, and rash in a child with fever and elevated IgD seems to make MK deficiency less
likely. The same applies to the absence of diarrhoea. Diarrhoea was present in all MK-
deficient cases and only in 2 of 4 patients with normal MK activity. One patient without MK
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deficiency was mentally retarded. However, 2 mentally retarded brothers with HIDS have
been reported in the literature (2) who were later shown to be mevalonate kinase deficient
(data not shown).
This study shows that HIDS is a heterogeneous disease. On the biochemical level most of the
patients show a MK deficiency. Here we report on 4 patients, who were originally
characterised as HIDS, but had a normal MK activity. Since the clinical differences were
discrete, determination of MK activity is the only certain way to differentiate these patients
from those who have MK deficiency. It remains to be determined, whether measurement of
urinary mevalonic acid excretion is equally reliable. The distinction between these groups is
important since MK deficiency is an autosomal recessive disease, with consequent
implications for genetic counselling. The defect or defects in the patients with periodic fever,
elevated IgD and normal MK activity are unknown at this moment. Despite the predominance
of boys, an X-linked disorder is unlikely, in view of the negative family history. Due to the
small size of Dutch families a negative family history does not rule out autosomal recessive
disease, which is illustrated by the 11 MK deficient children, none of whom had affected
siblings. One of the possibilities is that disorders of isoprenoid biosynthesis other than MK
deficiency could also cause periodic fever. Investigations to test this possibility are underway.
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Table 1
Registry number 1 26 61 72 88 119 129 132 135 137 139 142 50 136 138 140
Age (years) 18 8 6 9 8 11 8 12 2 5 5 8 17 8 6
Sex M/F M F F M M M M M F F F M M M M
Disease onset
(months)
3 1.5 3 5 3 3 6 0 11 3 12 2 160 42 4
Duration
of fever (days)2
3 7 4 5 4 4 4 3 4 4 3 3 4 7 4
Duration
of cycle (weeks)3
3 2 3 3 3 3 2 3 7 5 3 3 4 4 8
Malaise4 + + - + + + + + + + + + + + +
Chills - + - + + - - + - - - - - + +
Fever on
vaccinations
+ + + + + + + + + + + + - + +
Headache + + + + + + + + - - + - - + +
Abdominal pain + + + + + + + + - + + - + + +
Vomiting + + + + + + + + + - + - + - -
Diarrhoea + + + + + + + + + + + - + + -
Arthralgias + + + + + + + + + + + - + - -
Arthritis - - - - - - + + - + - - + - -
Rash + + + + + - + + + + + - - - +
Lymphadenopathy + + + + + - + + + + + + - + +
Splenomegaly - + - - + + + + - + + - - + -
Hepatomegaly + + - - + + + + - + + + - + -
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Table 2
Registry
number
IgGmax1
(g/l)
IgMmax1
(g/l)
IgAmax1
(g/l)
IgDmin2
(IU/ml)4
IgDsubmax3
(IU/ml)4
IgDmax
(IU/ml)3
Urinary
mevalonic
acid1,5
Mevalonat
e kinase
activity6
Mevalonate
kinase allotype7
26 11.9 1.4 7.9 n.a.8 1680 2040 5.4 1% V377I, H20P
61 24.5 3.1 2.3 210 571 1050 4.8 1% V377I, S135L
72 8.1 0.5 1.6 585 805 826 n.a.8 7% V377I, V377I
88 15.4 1.35 6.9 236 780 1107 22.4 4% V377I, R388X
119 11.9 1.65 2.55 338 338 505 41.5 3% V377I, H20P
129 17.3 2.8 1.9 550 571 1286 10.8 1% V377I, H20P
132 18.6 2.42 2.38 3 370 450 12.1 2% V377I, I268T
135 13.1 2.1 1.8 77 98 244 11.4 7% V377I, I268T
137 15.4 3.3 0.85 76 81 179 27.5 5% V377I, I268T
139 11.3 1.34 3.49 47 95 192 n.a8 5% V377I, V377I
142 28.2 7.45 4.5 66 92 158 21.7 4% V377I, I268T
50 12.5 1.8 3.1 89 209 209 <2 112% wild type
136 14 2 3.15 93 150 274 n.a.8 88% wild type
138 13.6 1.8 2.73 231 394 415 <2 90% wild type
140 12.6 2.2 1.25 157 160 181 <2 144% wild type
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Table 3
Mutant allele Coding effect frequency
59 A→C His 20→ Pro (H20P) 3/22
404T→C Ser 135→Leu (S135L) 1/22
803T→C Ile 268→Thr (I268T) 4/22
1129 G→A Val 377→ Ile (V377I) 13/22
1162 C→T Arg 338 →Stopcodon (R338X) 1/22
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Table 1
Characteristics of the patients.
1. Number refers to the entry number in the international Hyper IgD studygroup registry.
2. Duration of fever: the usual average duration of attacks as reported by parents at the time
of diagnosis.
3. Duration of cycle: the usual average duration between the onset of an attack and that of
the next attack as reported by parents at the time of diagnosis.
4. A symptom is recorded as positive when it has been present with at least one attack. The
data of patients with normal enzymatic activity are printed in italics.
Table 2
Immunoglobulin levels, mevalonic acid excretion, MK-activity and MK allotypes in 17
HIDS-patients.
1. Highest documented  value
2. Lowest documented value
3. Second highest documented value
4. Normal < 100 IU/ml. Where IgD had been reported in mg/l, the value was divided by 1.4
to convert to IU/ml.
5. Urinary mevalonic acid excretion in mmol/mol creatinine
6. Expressed as percentage of average activity in mononuclear cells from healthy control
persons, normal range (58-142%).
7. The allotypes were deducted from MVK cDNA mutation analysis (see text and table 3).
8. N.a.: not available
The data of patients with normal enzymatic activity are printed in italics.
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Table 3
Mutations identified in the cDNA of 11 mevalonate kinase deficient patients and their effect
on the mevalonate kinase protein . The frequency with which an allele was recognised among
the 2x11 mutant alleles found is given in the last column.
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Molecular basis of classical mevalonic aciduria and the hyperimmunoglobulinaemia D
and periodic fever syndrome: High frequency of 3 mutations in the mevalonate kinase
gene
S. M. HOUTEN 1, J. FRENKEL 2, W. KUIS 3, R. J. A. WANDERS 1, B. T. POLL -THE 4 and
H. R. WATERHAM 1*
1 Departments of Clinical Chemistry and Pediatrics, Emma Children’s Hospital, Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Departments of 2
General Pediatrics, 3 Immunology and 4 Metabolic Disorders, Wilhelmina Children’s
Hospital / University Medical Center Utrecht, Utrecht, The Netherlands
Correspondence: Department of Clinical Chemistry and Pediatrics (F0-226), Emma
Children’s Hospital, Academic Medical Center, University of Amsterdam, PO Box 22700,
1100 DE Amsterdam, T he Netherlands. E-mail : h.r.waterham@amc.uva.nl
The classical type of mevalonic aciduria (MA; MIM# 251170) is a rare autosomal recessive
metabolic disorder characterized by psychomotor retardation, failure to thrive,
hepatosplenomegaly and anemia. In addition, patients suffer from recur rent episodes of fever,
associated with lymphadenopathy, arthralgias, gastrointestinal problems and skin rash. The
disorder is caused by deficient activity of mevalonate kinase (MK). As a consequence of the
MK deficiency, high levels of mevalonic acid are present in plasma and urine of patients (1).
Recently, mevalonic aciduria was also recognized in patients with
hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS; MIM# 260920), who also
suffer from recurrent episodes of fever (2) (3). The mevalonic aciduria in HIDS patients,
however, was moderate and observed only during the febrile crises. MK enzyme activity was
decreased, but not fully deficient, varying between 1% and 4% residual activity (2). The
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diagnostic hallmark of HIDS is a constitutively elevated level of serum IgD, usually
accompanied by elevated levels of serum IgA (4). However, we recently identified patients
with the classical HIDS phenotype and MK deficiency but normal serum IgD levels (2).
Both syndromes are caused by mutations in the gene encoding MK. In HIDS, one missense
mutation, 1129G >A, was common to most patients analyzed so far(2;5). Most patients were
compound heterozygotes. At present, mutations in eight MA patients have been characterized
(6-9). In three patients an 803T >C mutation was identified for which a Mennonite ancestry
was suggested (7). This allele was also identified in two additional HIDS patients, suggesting
a high frequency of this mutation.
We describe here the frequency of these two mutations and a third common mutation in the
MK gene identified in eight new HIDS patients and calculate the allele frequency of these
mutations in all reported HIDS and MA patients. In addition, we make a comparison between
the genotypes of HIDS and MA patients.
MATERIALS AND METHODS
All patients studied were clinically diagnosed with HIDS and had strongly decreased
activities of MK as measured in fibroblasts and/or lymphocytes making use of 14C-labelled
mevalonate (10). Mutation analysis was performed on cDNA as described previously (9).
RESULTS AND DISCUSSION
Previous studies suggested that the 1129G >A mutation in the MK gene was the most
common cause of HIDS. We sequenced eight additional HIDS patients and identified nine
1129G >A alleles. One patient was homozygous; this was confirmed by sequencing parental
material. In addition, we identified four 803T >C alleles and one 59A >C allele. Both alleles
had previously been reported in other HIDS and MA patients, indicating a high frequency of
these alleles. Table 1 summarizes the frequency of these alleles in our patients and patients
diagnosed in other laboratories. The table includes data of only one affected member per
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family in those cases where more members have been identified. The 1129G >A mutation has
an allele frequency of 52% among HIDS patients. At present, only one HIDS patient has been
described who did not carry this allele (5). None of the MA patients carried the 1129G >A
allele, strongly suggesting that this mutation is responsible for the residual MK activity
measured in HIDS fibroblast lysates(2). Heterologous expression of this allele as a GST-MK
fusion protein in Escherichia coli revealed reduced enzyme activity. In addition, immunoblot
analysis showed a profound deficiency of the protein in lysates of skin fibroblasts of HIDS
patients, suggesting instability of the product of this allele in vivo (2). The estimated
frequency of the 803T >C allele among both HIDS and MA patients is 17%. Heterologous
expression of this mutant allele in E. coli resulted in strongly reduced MK enzyme activity.
Moreover, immunoblot analysis revealed low protein levels in an MA patient homozygous for
this allele (9). The fact that this severely affected MA patient died at an early age suggests
that the frequency of this allele might be underestimated owing to lethality in utero. This
allele was also identified in the only HIDS patient without the 1129G >A mutation, which
suggests that the second mutation identified in this patient, 500C >T, leads to the HIDS
phenotype. Heterologous expression of the resulting mutant enzyme and protein level analysis
by immunoblotting will be needed to determine the effect of this 500C >T mutation on the
enzyme. The third common allele, 59A >C, which encodes an inactive protein when
expressed in E. coli, has a frequency of 7% among HIDS and MA patients.
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Table 1
Frequency of three common mutations in the MK gene in HIDS and MA patients
Number of alleles in HIDS Number of alleles in MA
Coding
Effect
Mutation Our laboratory (a)
(24 alleles)
Other laboratories (b)
(18 alleles)
Frequency
(%)
Our laboratory (c)
(6 alleles)
Other
laboratories (d)
(10 alleles)
Frequency
(%)
V377I 1129G>A 14 8 52 0 0 0
I268TI 803Y>C 5 1 14 2 2 25
H20P 59A>C 3 0 7 1 0 6
a Houten et al (2); this work
b Drenth et al (5)
c Houten et al (9)
d Schafer et al (8); Hinson et al (6;7)
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ABSTRACT
Objective:
The Hyper IgD and periodic fever syndrome (HIDS) is an auto-inflammatory syndrome, in
which ex-vivo secretion of pro-inflammatory cytokines, such as Interleukin (IL)-1β, by
peripheral blood mononuclear cells (PBMC) is increased. HIDS is caused by a deficiency of
mevalonate kinase (MK).
How this inborn error in isoprenoid biosynthesis leads to inflammation is as yet unknown.
We investigated whether the increased IL-1β secretion is due to accumulation of mevalonate, the
substrate of the deficient enzyme or due to lack of its products, the isoprenoid compounds.
Methods:
The effects of lovastatin and of farnesol, geranylgeraniol, and mevalonate on PBMC from 8
patients with MK deficiency and from 13 controls were studied. Lovastatin inhibits isoprenoid
biosynthesis by reducing the production of mevalonate. Farnesol and geranylgeraniol restore
isoprenoid biosynthesis downstream from MK. Culture supernatants were collected for cytokine
analysis 48 hours after stimulation with monoclonal antibodies against CD2 + CD28.
Results:
Lovastatin induced a 9-fold rise in IL-1β secretion by normal anti-CD2 + CD28 stimulated cells
(p < 0.001). This effect could be countered by mevalonate, and, to a lesser extent, by farnesol
and geranylgeraniol. In the absence of lovastatin, mevalonate did not change IL-1β secretion.
MK deficient cells spontaneously secreted 9-fold more IL-1β than control PBMC (p < 0.005),
rising 2.4-fold in the presence of lovastatin. The effect of lovastatin on IL-1β secretion was
reduced by mevalonate, farnesol and geranylgeraniol.
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Isoprenoid biosynthesis in PBMC from patients is impaired due to the endogenous MK
deficiency. Bypassing this defect with farnesol, in the absence of lovastatin, led to a 62%
reduction (p < 0.02) in IL-1β secretion by these cells.
Conclusions
In this model, shortage of isoprenoid end products contributes to increased IL-1β secretion by
MK deficient PBMC, whereas excess mevalonate does not.
Key words
Mevalonic acid, fever, hyperimmunoglobulinaemia, immunoglobulin D, autoinflammatory,
Interleukin-1, cytokines, inflammation, lovastatin, farnesol.
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INTRODUCTION
The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), also known as Dutch
type periodic fever (MIM#260920), is an autosomal recessive disorder, characterized by febrile
attacks recurring at more or less regular intervals and the presence of an elevated serum IgD
concentration ( > 100 IU/ml)[1]. Over 170 patients have been diagnosed with the disease
worldwide [2]. Clinical features during the febrile attacks include cervical lymphadenopathy,
splenomegaly, hepatomegaly, skin rash, oral ulcers, vomiting, diarrhea, arthralgias, and arthritis.
Patients often complain of malaise, chills, headache, nausea or abdominal pain [1]. During these
febrile crises, blood tests reflect an acute inflammatory state, with leukocytosis and elevated
acute phase reactants e.g. C reactive protein.
Serum levels of pro-inflammatory cytokines, such as IL-6, and interferon gamma (IFN-γ), rise
during fever attacks [3;4]. Also, between attacks, isolated peripheral blood mononuclear cells
(PBMC) from HIDS patients secrete large amounts of pro-inflammatory cytokines, such as
interleukin (IL)-1β[5]. However, what causes the rise in production of these cytokines has
remained unclear.
In 1999, we and others identified the underlying genetic defect of the syndrome, namely
mutations in the gene MVK, which lead to a deficiency of the enzyme mevalonate kinase[6;7]
(MK). Mutations in the same gene are responsible for mevalonic aciduria (MA, MIM#251170), a
syndrome with episodic fever, mental retardation and dysmorphic features[8;9]. MK catalyses
the phosphorylation of mevalonic acid into 5-phosphomevalonate. It is the enzyme immediately
following 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase in the isoprenoid
biosynthesis pathway (Fig. 1)[10].
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This pathway produces cholesterol, which, in turn, is a precursor for steroid hormones, and bile
acids. Furthermore, this biosynthetic route yields a number of non-sterol isoprenoids. The latter
are hydrophobic molecules, such as dolichol and the polyisoprene side chains of heme-A and
ubiquinone. Non-sterol isoprenoids play a vital role in the prenylation of certain proteins. In this
process hydrophobic polyisoprene moieties are covalently attached to specific target proteins.
Prenylation comes in two forms, the attachment of farnesyl groups (from farnesylpyrophosphate)
or of geranylgeranyl groups (from geranylgeranylpyrophosphate).
In HIDS, the deficiency of MK causes accumulation in plasma of its substrate, mevalonic acid,
which is then excreted in the urine [6]. The causal link between mevalonate kinase deficiency
and inflammation remains to be clarified. Inflammation has to result from either the excess of
mevalonic acid or the shortage of one or more products of isoprenoid biosynthesis.
Recently, it has become apparent that impairment of isoprenoid biosynthesis can indeed
influence immune function. In vitro, inhibitors of HMG-CoA reductase, also known as statins,
may either suppress or enhance inflammatory responses, depending on the cell type studied and
the way in which these cells were stimulated. Many anti-inflammatory effects of statins have
been reported, including the reduction of lymphocyte proliferation, and of the expression of
MHC class II molecules, matrix metalloproteinases, cytokines, and chemokines [11-15]. On the
other hand, these compounds do have pro-inflammatory properties. Statins enhance endothelial
expression of cellular adhesion molecules [16]. Interestingly, the secretion of IL-1β, Interferon-γ
(IFN-γ) and IL-18 by PBMC stimulated ex-vivo with inactivated  M. tuberculosis is augmented
greatly by the inhibition of isoprenoid biosynthesis with statins[17]. The increased cytokine
secretion appeared to be T-helper1-cell-induced and to be due to lack of isoprenoids, since
addition of mevalonic acid reduced cytokine secretion to control levels.
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The question is, whether the reported increased secretion of pro-inflammatory cytokines in HIDS
could be explained along similar lines. If lack of isoprenoids were responsible, then addition of
isoprenoid intermediary metabolites to cells from HIDS patients should correct the cytokine
hypersecretion.
To be effective, these compounds should enter the isoprenoid pathway downstream from the
metabolic block in HIDS, i.e. beyond mevalonate kinase. Farnesyl pyrophoshate (FPP) and
geranylgeranyl pyrophosphate (GGPP) are such intermediary metabolites. Entry in living cells is
impaired, however, by the presence of hydrophilic pyrophosphate groups. The fatty alcohols
Farnesol (FOH) and geranylgeraniol (GGOH) are hydrophobic molecules that enter living cells
freely and, once inside, are converted into FPP and GGPP by two successive
monophosphorylations[18]. Therefore we studied the effects of FOH, GGOH, and mevalonate in
addition to lovastatin on the IL-1β secretion by
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PATIENTS AND METHODS
Patients
Pediatric HIDS or MA patients visiting our outpatient clinic for regular follow-up were
approached to participate in the study. After approval by the ethical review board and written
informed consent by the patients parents, blood was drawn by venipuncture in sterile pyrogen-
free heparinized plastic tubes. All patients were free of symptoms and not taking anti-
inflammatory drugs at the time of blood sampling. Healthy adult volunteers served as controls.
PBMC were isolated by Ficoll (Amersham Pharmacia Biotech, Uppsala, Sweden) density
gradient centrifugation. We incubated 1 x 105 cells per well in 96-well-flat-bottom microtiter
plates in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 5 % heat
inactivated fetal calf serum (Life Technologies, Grand Island, NY) filtrated through a 0.2 µm
filter, 2 mM L-glutamine and 1% penicillin-streptomycin. Incubations were performed in
quadruplicate at 37 °C in a humidified atmosphere containing 5 % CO2 in air. The cultures were
performed in the presence or absence of lovastatin (final concentration: 5 µM). In addition, either
1 mM mevalonate, 10 µM farnesol (FOH), 10 µM geranylgeraniol) GGOH, or 5 µM FOH/ 5 µM
GGOH or medium was added at the start of the experiments. Lovastatin, mevalonic acid, FOH
and GGOH were purchased from Sigma (St. Louis, MO). Both lovastatin, dissolved in ethanol,
and mevalonic acid lactone were converted to lovastatin and mevalonate respectively by
hydrolyzation (0.1M NaOH), followed by neutralization and stabilization at pH7.4 with 0.05M
HEPES and HCl (0.1M).
After 18 hours incubation either Mycobacterium tuberculosis, Purified Protein Derivative (PPD)
of  M. tuberculosis (Statens Serum Institut, Copenhagen, Denmark), mycobacterial heat shock
protein HSP60 (Sanbio, San Diego, CA), anti-CD2 + CD28 (PeliCluster CD 2.1, CD 2.2 and CD
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28, CLB Amsterdam, The Netherlands) or medium was added to the cultures without any other
change in the medium. The incubations were prolonged for an additional 48 hours. At the end of
the incubations supernatants were aspirated and stored at -20 °C until analysis.
Cytokine measurements
Cytokine concentrations were measured in thawed samples, using commercially available
enzyme-linked immunosorbent assays (PeliKine-compactTM human IFN-γ, IL-1β, IL-6 and TNF-
α ELISA kits CLB Amsterdam, The Netherlands). The assays were performed according to the
manufacturer’s instructions and all samples were tested in duplicate
Lymphocyte proliferation
PBMC at a concentration of 1 x 105 cells/well were cultured in 96 well flat-bottom microtiter
plates using the conditions as described above. After 48 hours of incubation, cells were pulse-
labeled with 1 µCi [3H] thymidine for 18 hours at 37 °C. Cells were harvested and [3H]
thymidine incorporation was measured in a liquid scintillation counter. Results were shown as
average counts per minute (cpm) of quadruplicate cultures.
Statistical analysis
The cytokine production under different conditions was compared by the Wilcoxon squared rank
test, with a 2-tailed p value of  < 0.05 being considered significant. Lymphocyte proliferation
was analyzed similarly. Values are displayed as mean +/- the standard deviation. All analyses
were performed using GraphPad Prism 3.0 software (GraphPad Software Inc., San Diego, CA)
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RESULTS
Patients
Seven HIDS patients participated in the study. These have been described previously, as
Numbers 119, 132, 135, 137, 139, 142 and 192 [19].
In all patients mevalonate kinase deficiency has been established and mutations have been
identified in both alleles of their MVK-genes. Two patients (a brother and sister) were
homozygous for the 1129 G > A (V377I) mutation, four patients were compound heterozygous
for the mutant alleles V377I and 803 T > C (I268T), and one patient carried the V377I and 59 A
> C (H20P) alleles. The mevalonic aciduria patient was a 2 year old boy, who presented with
episodes of high grade fever, anorexia, vomiting and macular rash. His mental development had
been adequate. His head circumference, though still normal, has grown slowly, but weight and
height gain have been excellent. He has no dysmorphic features. During febrile attacks he shows
markedly elevated acute phase reactants and neutrophil leukocytosis. Urine mevalonic acid was
extremely elevated (5461µmol/mmol creatinine). Mevalonate kinase activity in fibroblasts was
0.18 pmol/min.mg (0.12% of normal). He is compound heterozygote for the mutant alleles
1000G > A (A334T) and 421-422insG.
Cytokine secretion induced in normal mononuclear cells by anti-CD2 + CD28 can be augmented
by lovastatin.
We tested the ability of M. tuberculosis and several T-cell stimuli to induce statin sensitive
cytokine secretion (Fig. 2a). In the absence of lovastatin, the secretion of IL-1β was not
significantly stimulated by  M. tuberculosi , PPD, anti-CD2 + CD28, or HSP60. Lovastatin
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alone, i.e. without added T-cell stimuli, hardly induced any increase in IL-1β secretion (Fig. 2b).
However in the presence of both lovastatin and T-cell stimuli, IL-1β secretion rose 7-fold (PPD)
to 15-fold (anti-CD2 + CD28).
IFN-γ secretion was stimulated by M. tuberculosis, PPD, and by anti-CD2 + CD28.The latter
stimulus (anti-CD2 + CD28) elicited the strongest response. Combination with lovastatin
induced a modest further increase of IFN-γ secretion, but this did not reach significance (data not
shown). These stimuli did not induce secretion of IL-6. Neither did the secretion of IL-6 change
upon incubation with lovastatin (data not shown).
Since the anti-CD2 + CD28-induced cytokine secretion was equal or superior to that induced by
M. tuberculosis, PPD, or HSP60 and since this secretion was augmented consistently by
lovastatin, only anti-CD2 + CD28 was used as stimulus in all subsequent experiments
Cytokine secretion is not augmented by addition of mevalonate per se
In order to evaluate whether the augmented IL-1 secretion was due to accumulated mevalonate in
HIDS cells, the effects of exogenous mevalonate was studied in normal cells. In pilot
experiments we had determined that 1 mM mevalonate was sufficient to overcome the
antiproliferative effect of lovastatin without being toxic to the cells. In all subsequent
experiments, the 1 mM concentration of mevalonate was used.
In the absence of lovastatin, mevalonate induced no detectable effect on the secretion of IL-1β
(Fig. 2b), IFN-γ or IL-6. This implies that an excess of mevalonic acid is not responsible for the
increased cytokine secretion observed in HIDS.
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Mononuclear cells from HIDS and MA patients produce more IL-1β than control cells
Control cells excrete only small amounts of IL-1β (165 +/- 169 pmol/ml) when stimulated with
anti-CD2 + CD28. PBMC from HIDS patients excrete larger amounts of IL-1β (1685 +/- 1713
pmol/ml) than controls (p < 0.04). Cells from the mevalonic aciduria patient produced even more
IL-1β (4563 pmol/ml). HMG CoA reductase inhibition by lovastatin causes a further elevation of
IL-1β excretion by anti-CD2 + CD28-activated cells from both patients (2.4-fold rise; p < 0.05)
and controls (9.4-fold rise; p < 0.01) (Fig. 3). The spontaneous secretion of IL-6, known to be
elevated in HIDS, was also raised in MA (17028 pg/ml vs 2260 pg/ml in controls). IFN-γ
secretion in patients and controls was only detectable after anti-CD2 + CD28 stimulation and
tended to be higher (though not significantly) in HIDS cells than in control cells. IFN-γ secretion
by MA cells exceeded that of normal controls 3-4 fold.
The effect of lovastatin can be reversed by isoprenoid compounds, downstream from mevalonic
acid.
From previous experiments [17] it had become clear that mevalonic acid could abort the increase
in cytokine secretion, mediated by lovastatin. To see whether this was an effect of mevalonic
acid per se or one of its downstream metabolites, we studied the ability of FOH and GGOH to
correct this increased secretion.
In the supernatants of anti-CD2 + CD28 stimulated PBMC from normal healthy volunteers, IL-
1β secretion was increased 9-fold when cultured in the presence of lovastatin (Fig. 4a).
Mevalonate almost completely reversed this effect, reducing IL-1β secretion in the presence of
lovastatin by 88% (p < 0.01). FOH, also reduced IL-1β secretion by 45%. (p < 0.01). The effect
of GGOH was not statistically significant.
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These results indicate that compounds downstream of mevalonate in the isoprenoid biosynthetic
route can, at least in part, reverse the effect of lovastatin on IL-1β secretion. This implies that the
lack of such compounds might be responsible for the increased cytokine secretion observed in
the presence of lovastatin
IL-1β secretion in HIDS and MA is reduced by isoprenoid compounds downstream from
mevalonic acid
In the presence of lovastatin, IL-1β secretion by PBMC from HIDS patients is reduced by the
addition of FOH, GGOH or mevalonate (Fig. 4b). This effect is comparable to that observed in
normal controls. The single patient with MA displayed a similar pattern (Fig. 4c).
Apparently decreasing mevalonate availability by the addition of HMG-CoA reductase inhibitors
reduces isoprenoid output in HIDS and MA. This implies that, although affected patients are ill
due to the reduced mevalonate kinase activity, there is an important residual MK activity and the
enzyme does not become entirely and solely rate limiting.
The central question therefore was, whether downstream isoprenoids could correct the inherently
raised secretion of IL-1β in HIDS and MA. Indeed, in the absence of lovastatin, i.e. with the
endogenous mevalonate kinase deficiency being the only restriction on isoprenoid biosynthesis,
downstream isoprenoids could reduce IL1-β secretion (Fig. 5). In this situation, mevalonate was,
as expected, least effective, but FOH significantly reduced IL1-β secretion by 62% (p < 0.02).
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anti-CD2 + CD28 induced T-lymphocyte proliferation is impaired by lovastatin
The rise in IL-1β secretion in culture supernatants could not be explained by higher cell numbers
per culture well. Indeed, cell proliferation dropped by 62% in the presence of lovastatin (p <
0.001) (Fig. 6). Mevalonic acid completely reversed this effect. GGOH partially corrected the
effect of lovastatin. This effect was modest (15%), but significant (p < 0.01).
These data indicate that in this system lovastatin is effective and that its effect can be
antagonized by downstream isoprenoids in the concentrations employed.
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DISCUSSION
. In recent years the genes involved in 4 hereditary periodic fever syndromes have been
identified[6;7;20-23]. For two of these, MEFV, the gene mutated in familial Mediterranean fever
and CIAS1, the gene affected in both familial cold-induced autoinflammatory syndrome and the
Muckle-Wells syndrome, the functions are still unknown. In the TNF receptor associated
periodic syndrome, the link with inflammation is straightforward, since the affected gene
encodes the 55kDa receptor for tumor necrosis factor-α. In mevalonic aciduria and HIDS, the
picture is more complex.
HIDS is a well defined autoinflammatory disease[24]. There are recurrent episodes of
inflammation, reflected both in clinical signs and symptoms and in neutrophil leukocytosis and
raised acute phase reactants [1]. Between attacks, serum IgD and IgA are usually raised and
PBMC from HIDS patients secrete increased amounts of pro-inflammatory cytokines, notably
TNF-α and IL-1β. The gene affected in both conditions, MVK, encodes mevalonate kinase, an
enzyme involved in isoprenoid biosynthesis. However, how mevalonate kinase deficiency causes
inflammation is not known at present. The enzyme deficiency leads to an increase of its
substrate, mevalonate, and may lead to a shortage of end products, the isoprenoids (Fig. 1).
We adapted a model developed by Montero et al. [17] to test whether the increased cytokine
secretion in HIDS could be explained by the elevated mevalonate levels and / or decreased
isoprenoid production. In this model, isoprenoid output is reduced by lovastatin, which inhibits
HMG-CoA reductase, the enzyme preceding mevalonate kinase in the isoprenoid biosynthetic
pathway.
PBMC, stimulated with  M. tuberculosis in the presence of lovastatin reportedly secreted more
IFN-γ, IL-1β and IL-18 [17].
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Using a combination of T-cell stimulating monoclonal antibodies against CD2 and CD28, we
found that lovastatin causes a nine fold increase in IL-1β secretion by normal PBMC, though a
similar effect on IFN-γ secretion did not reach significance. Mevalonate, by itself, did not induce
IL1-β secretion. These observations therefore argue against mevalonate intoxication as the cause
of increased IL-1β in HIDS.
To test whether downstream isoprenoid metabolites could correct this hypersecretion of IL-1β,
we added either mevalonate, a precursor of farnesylpyrophosphate (FOH), or a precursor of
geranylgeranylpyrophosphate (GGOH) to the culture medium. Mevalonate corrects all branches
of isoprenoid synthesis, FOH, corrects mainly protein farnesylation and, to a lesser extent,
synthesis of other sterol and non-sterol isoprenoids, GGOH predominantly corrects
geranylgeranylation of proteins.
Spontaneous IL-1β secretion was elevated in PBMC from patients with HIDS and the one patient
with MA. The combination of lovastatin and anti-CD2 + CD28 induced a rise in IL-1β output in
both patients and controls. Mevalonate prevented this rise. Downstream isoprenoid metabolites
largely compensated the effect of lovastatin. This implies that some isoprenoid product or
products are necessary to prevent IL-1β secretion in this system. Which isoprenoid end products
are ultimately involved and how these interact with inflammatory pathways is the subject of
current research.
The finding that in HIDS cells that are largely mevalonate kinase deficient, inhibition of HMG-
CoA reductase would be of any consequence and that mevalonate could correct the effect of
lovastatin, is intriguing. Apparently, the residual MK activity (2 - 8%) is sufficient for changes in
the availability of mevalonate to be reflected in isoprenoid biosynthesis. Even in MA, the
enzyme deficiency, though profound, is not absolute and can, to a certain degree, be overcome
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by raised mevalonate levels. The main question was, however, what this means for the situation
in HIDS, i.e. in the absence of lovastatin. There, the endogenous mevalonate kinase deficiency is
the only impairment to isoprenoid biosynthesis. We showed that, in the absence of lovastatin,
FOH could inhibit the IL-1β production by HIDS cells.
We could not, however, reduce the spontaneous IL-1β secretion in HIDS to normal levels. This
could be due to insufficient rescue of isoprenoid biosynthesis in this model. In that case higher
concentrations of isoprenoids than those employed in the present study might be more effective.
Alternatively, mechanisms less directly related to reduced isoprenoid output, may contribute to
IL-1β hypersecretion in HIDS.
There is presently no effective treatment for either HIDS [2] or MA. If excess of mevalonic acid
were the cause of symptoms, then treatment with statins could be beneficial. A trial to that end is
underway in The Netherlands [2]. Experience with statins in MA has been disappointing,
however, with severe inflammatory attacks apparently provoked by the drug (9). Our findings
provide an explanation for this effect, since it is indeed the lack of downstream isoprenoids that
contributes to increased IL1β secretion in HIDS.
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Figure 1
Isoprenoid biosynthesis pathway. Statins inhibit the early enzyme, HMG-CoA reductase.
Numbers represent: 1: the defect in HIDS and MA is a deficiency of mevalonate kinase, 2: point
of entry of farnesol (FOH), a precursor of farnesyl pyrophosphate and 3: point of entry of
geranylgeraniol (GGOH) a precursor of geranylgeranyl pyrophosphate.
Figure 2
J.Frenkel et al.Lack of isoprenoids raises IL-1β in HIDS #02-0191-FL marked revision
Page 22
a) Mean
interleukin (IL)-1β
secretion by
mononuclear cells
from healthy adult controls (n=2) incubated in the absence (-) or presence (+) of 5 µM
lovastatin. T-cell stimuli were none (Medium),  M. tuberculosis (M.tbc), PPD of  M.
tuberculosis (PPD), anti-CD2 + CD28 (CD2CD28), and mycobacterial heat shock protein
(HSP 60).Error bars represent standard deviation (SD)
b) IL-1β secretion by normal mononuclear cells incubated with (from left to right) medium
control, anti-CD2 + CD28, 1mM mevalonate, 5 µM lovastatin, or both lovastatin and
anti-CD2 + CD28. Data are means + 1SD from 13 donors tested in 6 independent
experiments. Values significantly (p < 0.05) different from the IL-1β concentrations
obtained with medium only are marked (*).
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Figure 3
IL-1β secretion (mean + 1SD) by mononuclear cells from 13 controls, 7 hyper IgD syndrome
(HIDS) patients and one mevalonic aciduria (MA) patient. Cells were incubated for 18 hrs in the
absence (left panel) or presence (right panel) of 5 µM lovastatin and stimulated for 48 hrs with
anti-CD2 + CD28.
Figure 4
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IL-1β secretion (mean + 1SD) by mononuclear cells, stimulated with anti-CD2 + CD28, from
adult controls (panel a, n = 10), HIDS patients (panel b, n = 7) and one MA patient (panel c).
Cells were incubated in the presence of culture medium only (Medium) or with the indicated
combinations of 5 µM lovastatin (Lova), 10 µM Farnesol (FOH), 10 µM Geranylgeraniol
(GGOH), 1 mM mevalonate (Mev).
Values significantly (p < 0.05) different from the IL-1β concentrations obtained with the
combination of lovastatin and anti-CD2 + CD28 are marked (*).
Figure 5
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IL-1β secretion (mean 1SD) by mononuclear cells from HIDS patients (panel a, n = 7) and one
MA patient (panel b), stimulated with anti-CD2 + CD28.in the absence of lovastatin. Cells were
incubated in the presence of culture medium only (Medium), 10 µM FOH, 10 µM GGOH, or 1
mM mevalonate (Mev).Values significantly (p < 0.05) different from the IL-1β concentrations
obtained with only anti-CD2 + CD28 stimulation are marked (*).
Figure 6
J.Frenkel et al.Lack of isoprenoids raises IL-1β in HIDS #02-0191-FL marked revision
Page 27
Proliferation of mononuclear cells from controls (n = 11), stimulated with anti-CD2 + CD28.
Bars represent mean 3H-thymidine incorporation + 1SD Cells were incubated in the presence of
culture medium only (Medium), or in the presence of the indicated combinations of 5 µM
lovastatin (Lova), 10 µM FOH, 10 µM GGOH, 1 mM mevalonate (Mev).
Values significantly (p < 0.05) different from the 3H-thymidine incorporation obtained with the
combination of lovastatin and anti-CD2 + CD28 are marked (*).
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Abstract
Objective:
The Hyper IgD and periodic fever syndrome and mevalonic aciduria are,
characterized by recurrent episodes of generalized inflammation. Both
syndromes are caused by a deficiency of mevalonate kinase. How this inborn
error in isoprenoid biosynthesis leads to inflammation and which cells are
involved in this process is as yet unknown.
We investigated whether specific leukocyte populations are activated during
the fever attacks in children with mevalonate kinase deficiency.
Methods:
Blood samples obtained during and in-between fever attacks were analyzed by
white-cell and differential counting and by flow-cytometry. Cells were studied
for the expression of CD3, CD4, CD8, CD14, CD20, CD23, CD64, CD69 and
HLA-DR.
Results:
6 patients were studied. During fever monocyte numbers rose 3-fold and
neutrophil granulocytes 4-fold. These cells were activated, as reflected by the
expression of CD64, which was increased 3-fold on monocytes and 6-fold on
granulocytes. There were no such changes in other leukocyte subsets.
Conclusions
Activation of monocytes and neutrophil granulocytes is involved in the fever
attacks of the Hyper-IgD and periodic fever syndrome.
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Introduction
The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), also
known as Dutch type periodic fever (MIM#260920), is an autosomal recessive
disorder, characterized by febrile attacks recurring at more or less regular
intervals and the presence of an elevated serum IgD concentration (>100
IU/ml)(1). Over 170 patients have been diagnosed with the disease worldwide
(2). Clinical features during the febrile attacks include cervical
lymphadenopathy, splenomegaly, hepatomegaly, skin rash, oral ulcers,
vomiting, diarrhea, arthralgias, and arthritis. Patients often complain of
malaise, chills, headache, nausea or abdominal pain (1). During these febrile
crises, blood tests reflect an acute inflammatory state, with leukocytosis and
elevated acute phase reactants e.g. C reactive protein. The underlying genetic
defect of the syndrome, is a deficiency of the enzyme mevalonate kinase (MK)
due to mutations in its encoding gene, MVK.(3,4). Mutations in the same gene
are responsible for mevalonic aciduria (MA, MIM#251170), a syndrome with
episodic fever, mental retardation and dysmorphic features(5,6). MK catalyses
the phosphorylation of mevalonic acid into 5-phosphomevalonate, an early
step in the isoprenoid biosynthesis pathway. This route produces cholesterol,
which, in turn, is a precursor for steroid hormones, bile acids and vitamin D.
Furthermore, this anabolic route yields a number of non-sterol isoprenoids.
The latter are hydrophobic molecules, such as dolichol, the polyisoprene side
chains such as those attached to heme-A and ubiquinone and the farnesyl and
geranylgeranyl side chains, of isoprenylated proteins. Presently, the chain of
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events that links this metabolic defect to episodic inflammation is understood
only partly. Indeed, much has been learned about the soluble pro- and anti-
inflammatory mediators, involved in HIDS. Patient serum contains high levels
of pro-inflammatory cytokines, such as interferon-γ and interleukin (IL)-6
(7,8) during fever attacks and ex-vivo, isolated mononuclear cells (MNC)
from HIDS patients secrete more IL-1β, IL-6, and TNF-α than MNC from
healthy individuals.
It is as yet not known which leukocyte subpopulation(s) are involved in the
inflammatory activation that characterizes HIDS. We therefore analyzed
leukocyte (sub)populations in peripheral blood of patients during and in-
between fever attacks.
Our aim was to establish, whether there were quantitative changes in
leukocyte subpopulations and whether one or more of these cell types
appeared to be activated in mevalonate kinase deficiency.
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Patients and methods
Pediatric mevalonate kinase deficiency patients with either the HIDS or the
MA phenotype, visiting our outpatient clinic for regular follow-up, were
approached to participate in the study. After approval by the ethical review
board and written informed consent by the patients parents, blood was drawn
by venipuncture in sterile pyrogen-free heparinized plastic tubes as well as in
500 µl EDTA- anticoagulated plastic cups . This was done both when patients
were free of symptoms and within the first 24 hours of a febrile attack. EDTA
samples were used for white blood cell counting and white cell differential
counting (Cell-Dyn 4000, Abbott Diagnostics, Santa Clara, CA). The
heparinized samples were kept on ice from the moment of venipuncture until
flowcytometric analysis, in order to prevent granulocytes from being
activated. Patients were not taking anti-inflammatory drugs at the time of
blood sampling. Healthy adult volunteers served as controls.
100 µl aliquots of heparinized whole blood were incubated on ice during 30
minutes with diluted antisera. These murine monoclonal sera were directly
labeled with Fluorescine IsoThioCyanate (FITC) or phycoerythrin (PE) and
added to a final dilution of 1:10 for anti CD64-FITC (Immunotech, Marseille,
France) and 1:100 for all other monoclonals. These were anti-CD3-FITC with
anti HLA-DR-PE, anti-CD4-FITC with anti-CD8-PE, anti-CD69-FITC with
anti-CD3-PE, anti-CD20-FITC with anti-CD23-PE, and anti-CD14-PE
(Becton Dickinson Immunochemistry systems, San Jose, CA). Samples were
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then washed with phosphate buffered saline (PBS) with 1% bovine serum
albumin (BSA) and 0.02% NaAzide and after centrifugation at 1500 rpm red
cells were lysed during 20’with 2 ml FACS Lysing Solution (Becton
Dickinson Immunochemistry systems, San Jose, CA), centrifuged and
resuspended twice in 0.01% Na-Azide in PBS. Immunofluorescence was
measured with a FACS Calibur flowcytometer and analyzed with Cell Quest
software (Becton Dickinson Immunochemistry systems, San Jose, CA). Cell
populations were identified by scatter pattern (granulocytes vs. mononuclear
cells). Subpopulations with a specific surface marker profile were expressed as
percentage of mononuclear cells. Expression of CD 23 and CD 64 was
measured as mean fluorescence intensity (MFI) of those markers on the
(sub)population studied. To correct for inter-assay variability of MFI
measurements, the MFI was expressed as the ratio of the value obtained in the
patient sample and that obtained in a simultaneously tested sample of a healthy
adult control.
Statistical analysis
Cell counts during and in-between fever attacks were compared by the
Wilcoxon squared rank test, a 2-tailed p value of <0.05 being considered
significant. Fluorescence intensity was similarly analyzed. Values are
displayed as mean ± the standard deviation. All analyses were performed
using GraphPad Prism 3.0 software (GraphPad Software Inc., San Diego, CA)
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Results
Patients
Six mevalonate kinase deficiency patients participated in the study. Five of
these had the HIDS phenotype. These have been described previously, as
Numbers 119, 132, 135, 137 and 139.(9). One child had the mevalonic
aciduria phenotype.
In all patients mevalonate kinase deficiency has been established and
mutations have been identified in both alleles of their MVK-genes. Four were
compound heterozygous for the mutant alleles 1129 G>A (V377I) and 803
T>C (I268T), and one patient carried the V377I and 59 A>C (H20P) alleles.
The mevalonic aciduria patient has been described elsewhere (chapter 7). He
has only 0.12% residual mevalonate kinase activity, due to mutations
1000G>A and 421-422insG in his MVK genes.
White blood cell and differential counts were obtained during and in-between
febrile episodes in all 6 patients. In five of these, these data could be obtained
during 2 fever episodes and in 2 or 3 non-febrile intervals.
Immunocytochemical analysis was performed at least once during fever and
once in-between attacks.
White blood cells
The fever attacks were characterized by leukocytosis which sometimes was
extreme (>40x109/l). Leukocytes on average rose from 7.7x109/l between
attacks to 18.9x109/l during fever (p=0.001).
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Lymphoid cells
During fever attacks, the percentage of lymphocytes in the differential count
decreased 4-fold. This was largely due to a rise in myeloid cells. Absolute
lymphocyte numbers showed little decrease. (Table 1)
T-lymphocytes
Absolute T-cell numbers, as determined by CD3 expression were similar in-
between and during  fever attacks. There was a slight decrease of T-cells as a
percentage of mononuclear cells during fever (Table 2). However, both
absolute and percentual T-cell counts were normal for age (10).
CD4 and CD8 subsets were normal for age and remained stable during and in-
between attacks (Table 2) as did the CD4 / CD8 ratio.
The proportion of T-cells expressing CD69, an early activation marker, in-
between attacks (0.4-1.4%) was comparable to that observed by us in 41
healthy adult controls (1.1-1.4%). During fever there was a small  increase in
CD69 expression (Table. 2). The percentage of T-cells that expressed HLA-
DR was very similar in-between and during fever and well within the normal
range (10).
B-lymphocytes
The percentage of B-lymphocytes as determined by CD20 expression
remained normal in-between and during fever episodes, as did absolute B-cell
numbers (table 2). B-cell activation was assessed by the MFI of the Fc-
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epsilon-Receptor II, CD23, on CD20 positive cells. B-cell activation between
attacks was comparable to that in healthy adult controls. During fever there
was no significant change.
Monocytes
Monocyte numbers rose 2.8-fold during fever attacks. This was not reflected
in the monocyte percentage in the differential count, because of a concomitant
rise in granulocytes (Table. 1). Activation of monocytes was assessed by the
presence on the cell surface of CD64 (Fcgamma-Receptor I). Monocytes were
identified by the expression of the lipopolysaccharide receptor CD14 (Figure
1a). Activation was quantitatively expressed as the ratio of MFI of CD64 on
CD14- positive cells of patients over that on CD14- positive cells of healthy
adult controls (Table. 2). During fever there was a 2.5-fold rise in CD64
expression on monocytes (p=0.03, Figure 1b).
Granulocytes
Neutrophil leukocytosis during attacks was striking (Table. 1) with absolute
neutrophil counts rising over 4-fold (p<0.001). Band forms were present in a
minority of patients during fever, but could be as high as 15%.Eosinophil
counts decreased during fever (table 1).
CD64 expression was measured on granulocytes, i.e. on cells that had the light
scattering characteristics of granulocytes on flow-cytometry (Figure 1c) and
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were negative for CD14. The MFI of CD64 rose 6.4-fold during fever
(p<0.01).
These changes in both number and degree of activation of monocytes and
neutrophil granulocytes constituted the main abnormalities observed in
mevalonate kinase deficient patients (Figure 1).
Discussion
Mevalonate kinase deficiency leads to recurrent bouts of generalized
inflammation. The chain of events linking the metabolic defect to the
inflammatory phenotype is understood incompletely. Somehow inflammatory
effector mechanisms are activated. We aimed to determine in which cell
population this occurred. Several leukocyte subsets, could be expected to be
activated in this disorder. B-lymphocytes might be involved, as suggested by
the polyclonal elevation of IgD and IgA, typical of HIDS(11). T-lymphocytes,
had been implicated previously, because of the high serum concentrations of
interferon-gamma during fever attacks(8). Cells of the monocyte/macrophage
lineage were expected to be activated. Inflammatory mediators typically
produced by such cells, have been found to be secreted in increased amounts
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either in-vivo, ex-vivo or both(7,12). Also, the raised urinary neopterin
excetion is indicative of activation of mononuclear phagocytes (7). Finally,
neutrophil granulocytes could be involved, since granulocytosis is a well
known feature of the fever attacks in mevalonate kinase deficiency(1).
Despite the small number of patients studied, our data indicate that it is mainly
the non-specific immune system, that is activated during fever episodes.
We could not detect signs of B-cell activation. T cells were not increased in
numbers, nor was there increase in HLA-DR expression. The increase in
CD69 expression on T-lymphocytes, though statistically significant, was very
modest. It’s biological significance, therefore, remains uncertain.
In contrast, there was a 4-fold increase in the numbers neutrophil granulocytes
and a 3-fold rise in monocyte numbers. Moreover, these cells were activated,
as reflected by the raised expression of CD64.
It can not be excluded, that these phagocytic myeloid cells are activated
indirectly by some other cell population. Blood sampling during attacks took
place as soon as fever had become manifest, so any activation preceding the
onset of fever would not have been detected. It is conceivable that T-
lymphocytes are involved in the initiation of the fever episodes, since these
attacks are often triggered by immunizations or infections and the serum
concentration of T-cell derived cytokines is elevated in HIDS. Also, the
activation of non-circulating cells, such as plasma cells (responsible for IgA ad
IgD secretion) sessile macrophages or dendritic cells would not have been
detected by the present study.
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However, the analogy with the other hereditary periodic fever syndromes
would favor a central role for granulocytes and monocytes. Like HIDS, these
are genetically determined autoinflammatory diseases, i.e. disorders in which
inflammation is prominent but neither infectious organisms nor auto-reactive
lymphocytes or auto-antibodies are involved (13). In two of these, Familial
Mediterranean Fever (FMF) and the Cold-Induced Auto-Inflammatory
syndrome / Muckle-Wells syndrome complex, the affected gene is expressed
exclusively in granulocytes and monocytes (14,15,16). In the third
autoinflammatory disorder for which the gene defect is known, the autosomal
dominant TNF-Receptor Associated Periodic Syndrome, the 55kD high-
affinity receptor for Tumor Necrosis Factor-alpha, is mutated(17). This
receptor is expressed on many cell types, but among leukocytes, it is present
only on granulocytes and monocytes. We have observed that the deficiency of
mevalonate kinase worsens during fever. Moreover, further impairment of
isoprenoid biosynthesis does augment the secretion of IL-1β by mononuclear
cells upon stimulation via T-cells (JF and SH, unpublished). The body of data,
therefore favors a model in which, the initiation of an attack may involve T-
cell activation. The consequent activation of mononuclear and, ultimately,
polymorphonuclear phagocytes, however, runs out of control due to the
metabolic defect. These cells, and the soluble mediators they produce, then
give rise to the symptoms patients suffer during their attacks. It has been
hypothesized that the periodic fever syndromes result from impaired apoptosis
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of (18). However, whether impaired apoptosis is instrumental in the observed
increase of monocytes and neutrophils in this study remains to be investigated.
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Table. I
White blood cell and differential counts in mevalonate kinase deficiency
patients during and in-between fever attacks.
non febrile febrile p*
n 14 11
white blood cells x109/l 7.65 (± 3.20) 18.93 (± 5.7) 0.001
neutrophil granulocytes§ x109/l 3.72 (± 3.03) 14.95 (± 5.97) 0.001
polymorphonuclear granulocytes % 46.5 (± 20.2) 78.8 (± 9.1) 0.003
band forms % 0 2.4 (± 4.4) n.s.
eosinophil granulocytes x109/l 0.12 (± 0.08) 0.02 (± 0.05) 0.004
" % 1.8 (± 1.3) 0.2 (± 0.4) 0.002
monocytes x109/l 0.38 (± 0.16) 1.07 (± 0.59) 0.001
" % 5.5 (± 2.0) 5.9 (± 3.2) n.s.
lymphocytes x109/l 3.42 (± 1 1.78) 1.91 (± 0.82) 0.024
" % 46.1 (± 19.4) 11.0 (± 6.1) 0.001
Values are means (± standard deviation)
* 2-tailed Wilcoxon squared rank test
§ sum of polymorphonuclear granulocytes and band forms
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Table. II
Immunocytochemical analysis of leukocytes of mevalonate kinase deficiency
patients during and in-between fever attacks.
non febrile febrile p*
n 10 9
T-lymphocytes
CD3 x109/l 2.38 (± 1.02) 2.09 (± 1.16) n.s.
CD3 %§ 74.2 (± 4.05) 61.1 (± 11.1) 0.008
CD4 % 39.8 (± 9.7) 40.8 (± 9.9) n.s.
CD8 % 22.4 (± 9.1) 15.5 (± 6.9) n.s.
HLA-DR on CD3+ve cells %¶ 5.2 (± 2.5) 4.0 (± 1.3) n.s.
CD69 on CD3+ve cells %¶ 1.0 (± 0.5) 2.5 (± 0.9) 0.008
B-lymphocytes
CD20 x109/l 0.26 (± 0.20) 0.58 (± 0.45) n.s.
CD20 % 8.8 (± 4.2) 15.2 (± 9.5) n.s.
MFI# of CD23 on CD20 0.80 9(± 0.32) 0.61 (± 0.45) n.s.
myeloid cells
MFI of CD64 on CD14+ve cells 1.33 (± 0.59) 3.30 (± 1.75) 0.031
MFI of CD64 on granulocytes 1.72 (± 0.99) 11.0 (± 11.8) 0.008
values are means (± standard deviation)
* 2-tailed Wilcoxon squared rank test
§ expressed as percentage of mononuclear cells
¶ percentage of CD3 positive cells
# MFI expressed as ratio over simultaneously tested healthy adult control
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Legends
Figure 1
CD64 expression on granulocytes and monocytes.
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Data are from a representative when febrile and in-between fever attacks.
Panel a) Dot plot of forward scatter (side scatter (SSC). vs.
immunofluorescence with anti CD14-PE. Analyses on monocytes were
performed on cells within the indicated gate. Panel c) Dot plot of forward
scatter (FSC) vs side scatter (SSC). Analyses on granulocytes were performed
on cells within the indicated gate. Panels b) and d) CD64 fluorescence
intensity on monocytes (panel b) and granulocytes (panel d) when febrile
(black histograms) and in-between fever attacks (white histograms)
Frenkel et al. Leukocyte activation in HIDS 24
Figure 1
Increased urinary leukotriene E4 during febrile attacks in the hyperimmunoglobulinaemia
D and periodic fever syndrome.
Joost Frenkel1, Michel A. A. P. Willemsen2, Corrie M. R. Weemaes3, Lambertus
Dorland4, Ertan Mayatepek5
Departments of General Pediatrics (1) and metabolic diseases (4) Wilhelmina Children’s
Hospital / University Medical Center, Utrecht, The Netherlands. Departments of Pediatric
Neurology (2), and Pediatrics (3) University Medical Center St Radboud, The
Netherlands. Division of Metabolic and Endocrine Diseases, University Children’s
Hospital, Heidelberg, Germany (5).
Corresponding author
Joost Frenkel, MD
Div. of Pediatrics Wilhelmina Children's Hospital
KE.04.133.1, University Medical Center Utrecht
PObox 85090, 3580AB Utrecht, The Netherlands
e-mail j.frenkel@wkz.azu.nl
tel +31 30 2504001, fax +31 30 2505349
Abstract
Background:
The hyperimmunoglobulinaemia D and periodic fever syndrome is a
hereditary periodic fever, caused by deficiency of the enzyme mevalonate kinase. It is
unclear how this defect leads to recurrent fever episodes.
Aim:
To assess the involvement of cysteinyl leukotrienes in the pathogenesis of fever attacks
as reflected by urinary leukotriene E4 (LTE4) excretion.
Methods:
Urinary LTE4 was measured in seven patients while febrile and afebrile
Results—LTE4 was raised during fever in all subjects (46–199 nmol/mol creatinine,
mean 92; normal <40). Urinary LTE4 was normal between attacks, as well as in normal
children with fever as a result of miscellaneous causes.
Conclusion:
Our results suggest that cysteinyl leukotrienes play a role in the pathophysiology of this
disorder. As no effective treatment is yet available, leukotriene receptor antagonists
might offer a new therapeutic approach for patients with the hyperimmunoglobulinaemia
D and periodic fever syndrome.
(Accepted 26 April 2001. Arch Dis Child 2001;85:158–159)
Keywords: cysteinyl leukotrienes; leukotriene E4; mevalonate kinase; periodic fever;
immunoglobulin D
Dutch type periodic fever (MIM#260920), also known as the hyperimmunoglobulinaemia
D syndrome (HIDS), is an autosomal recessive disorder, characterised by febrile attacks
recurring at more or less regular intervals and the presence of an increased serum IgD
concentration(1). Temperature typically rises abruptly, remaining continuously increased
for three to six days. Febrile episodes recur every two to eight weeks from infancy.
During these attacks patients often complain of malaise, chills, headache, arthralgias,
nausea, vomiting, diarrhoea, and abdominal pain. The affected children often have
striking cervical lymphadenopathy and may have splenomegaly, hepatomegaly, arthritis,
and a variety of skin rashes (2). In the patient’s blood, markers of inflammation such as
white cell counts, erythrocyte sedimentation rate, and serum concentrations of several
proinflammatory cytokines, are raised during febrile episodes (3), and the urine
concentration of neopterin is acutely raised (4). Mutations in the MVK gene, which
encodes mevalonate kinase, have been identified as the underlying genetic defect (5;6).
These mutations lead to a substantially reduced activity of mevalonate kinase, a key
enzyme in the biosynthesis of cholesterol and other isoprenoid compounds.
Another disorder, mevalonic aciduria7 (MA, MIM# 251170), has been described in
which mutations in the MVK gene virtually abolish all enzyme activity of mevalonate
kinase (7;8). This disease is characterised by failure to thrive, developmental delay,
hypotonia, seizures, cerebellar ataxia, hepatosplenomegaly, anaemia, and a dysmorphic
facies. Patients with MA suffer from recurrent attacks of generalised inflammation,
similar to those observed in HIDS, but often more severe (9).
The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are endogenous lipid molecules
derived from arachidonic acid through the 5-lipoxygenase pathway (10). These
compounds are very potent proinflammatory mediators, acting at subnanomolar
concentrations. Several cell types are capable of producing cysteinyl leukotrienes,
including macrophages, eosinophils, and mast cells. Endogenous urinary LTE4 excretion
is a reliable index of the systemic production of cysteinyl leukotrienes in vivo (11). The
pathogenesis of inflammation in both MA and HIDS remains unknown. However, in
patients with mevalonic aciduria urinary excretion of LTE4 was found to be highly
increased , suggesting a pathogenic role for cysteinyl leukotrienes in MA (12;13). In the
present study, we tested the hypothesis that cysteinyl leukotrienes are similarly involved
in HIDS.
Patients and methods
After obtaining informed consent, urine samples were collected from seven children
(aged 7–13 years), whose diagnosis of HIDS had been confirmed by demonstration of
mutations in both copies of the MVK gene. From each case samples were obtained twice,
once during a fever episode and once between attacks. Clinically, the fever could be
attributed to an attack of HIDS (and not to an intercurrent infectious disease). Samples
were collected in polypropylene containers and either immediately frozen and stored at -
80°C (cases 1–3) or frozen at -20°C, thawed, transferred to smaller containers, and then
stored at -80°C (cases 4–7) until analysis. The presence of pathological constituents was
excluded.
Mevalonate concentrations were determined with a stable isotope dilution assay and gas
chromatography–mass spectroscopy (5). Urinary LTE4 was measured as described
previously (11;14). Briefly, 3H- LTE4 (Du Pont–New England Nuclear, Boston,
Massachusetts) was added as an internal standard. All urine samples were then acidified
to pH 4.5 by addition of 0.1 mol/l HCl. Extraction of LTE4 was performed on Sep-Pak
C18 cartridges (Waters Associates, Milford, Massachusetts); separation of LTE4 from
other leukotrienes was carried out by reversed phase high pressure liquid
chromatography. Quantification of LTE4 was performed by enzyme immunoassays with
specific antibodies (Cayman, Ann Arbor, Michigan). The corresponding specificity for
the LTE4 antibody was 100% for LTE4, 10% for LTC4, 9% for LTD4, and <0.01% for
LTB4.
Statistical analysis was performed using a paired samples t test (SPSS 8.0).
Results
Between fever episodes the mean urinary LTE4 excretion in HIDS patients was 36 (range
30–40) nmol/mol creatinine, well within the normal limit (<40 nmol/mol creatinine).
Figure 1
Urinary LTE4 concentrations during and between fever episodes.
During fever episodes, urinary excretion of LTE4 increased in all patients (mean 92, range
46–199 nmol/mol creatinine; fig 1). This was significantly higher than the values
recorded when patients were afebrile (p = 0.036). As expected in HIDS, the
concentrations of mevalonic acid in urine were increased during fever periods. However,
there was no correlation between urinary concentration of mevalonic acid (4.2–41.5
mmol/mol creatinine; normal <0.1 mmol/mol creatinine) and that of LTE4 (data not
shown). In addition, urinary LTE4 was found to be within normal limits (30.8 ±6.5)
nmol/mol creatinine) in 20 infants and children with fever caused by viral or bacterial
infections as well as fever of unknown origin, recruited from outpatients and inpatients at
the University Children’s Hospital, Heidelberg, Germany. Urinary LTE4 remained
unchanged in the same group of otherwise normal children when afebrile (31.4 ±6.3)
nmol/mol creatinine).
Discussion
Cysteinyl leukotrienes have a pathophysiological role as mediators of inflammation in
disease states like bronchial asthma, juvenile rheumatoid arthritis, or inflammatory bowel
disease(15;16). In addition, LTE4 excretion was found to be enhanced in the most severe
form of mevalonate kinase deficiency, MA (12). In this disorder and in contrast to HIDS,
urinary LTE4 is constantly raised, even though the highest values are found during febrile
episodes. In this study, we showed increased excretion of LTE4 in seven patients with the
mild form of mevalonate kinase deficiency, HIDS, during fever, but not between attacks.
The concentrations of LTE4 during the attacks of cases 4–7 (open symbols in fig 1) were
lower than those in the clinically equally severe cases 1–3 (closed symbols in fig 1),
which in part might reflect the temporary thawing of urine samples in combination with
the instability of LTE4. However, independently from the storage procedure, all urine
samples from the patients with HIDS showed significantly raised LTE4 concentrations
during fever episodes.
Although the number of patients is small, our data point to a role of cysteinyl leukotrienes
in the pathogenesis of the episodic inflammation in HIDS. While increased LTE4
excretion is not specific for MA or HIDS, it is not merely a consequence of fever, as
urinary LTE4 is not raised in children with fever caused by viral or bacterial infections.
The introduction of cysteinyl leukotriene receptor antagonists should help to elucidate the
role of these mediators in HIDS. It is speculative whether such agents could reduce the
severity of fever attacks in HIDS. As these have thus far been resistant to all current anti-
inflammatory treatment (2), a
future new therapeutic approach would be most welcome.
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Abstract
Hyper IgD and periodic fever syndrome (HIDS) and mevalonic aciduria (MA) are autosomal
recessive disorders characterized by recurrent episodes of fever and generalized
inflammation. Both syndromes are caused by specific mutations in the gene encoding
mevalonate kinase (MK), resulting in a depressed enzymatic activity mainly due to reduced
protein levels. We studied the effect of temperature on the activity of wildtype and several
mutant MKs in fibroblasts. All fibroblast cell lines originating from HIDS patients and
harboring the common V377I MVK allele, displayed substantially higher MK activities at
30°C as compared to 37°C. As shown by temperature inactivation experiments this resulted in
a protein nearly as stable as in control cell lines, indicating that it is primarily the maturation
of the protein which is affected. Accordingly, when HIDS cell lines were cultured at 39°C,
MK activity decreased further. This triggered a compensatory increase in 3-hydroxy-3-
methylglutaryl-CoA reductase activity indicating that MK becomes progressively rate-
limiting. A similar phenomenon occurs in vivo. MK activity in peripheral blood mononuclear
cells drops 2-6-fold when HIDS patients experience febrile attacks. Thus, minor elevations in
temperature, can set off a chain of events, with MK becoming progressively rate-limiting,
leading to a temporary deficiency of isoprenoid end-products, followed by inflammation and
fever.
Keywords: mevalonic acid, hypergammaglobulinemia, Immunoglobulin D, mutation,
syndrome, inflammation, lipid metabolism
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Introduction
Recurrent fever and generalized inflammation are the hallmarks of auto-inflammatory
diseases, which include the hereditary periodic fever syndromes such as familial
Mediterranean fever, TNF-receptor associated periodic syndromes, hyper IgD and periodic
fever syndrome (HIDS, MIM 260920) and mevalonic aciduria (MA, MIM 251170)(1). HIDS
and MA are relatively rare autosomal recessive diseases and are caused by a depressed
activity of the enzyme mevalonate kinase (MK, EC 2.7.1.36)(2-4). In both MA and the more
benign HIDS, patients suffer from recurrent fever episodes associated with lymphadenopathy,
arthralgias, vomiting, diarrhea and skin rash (5;6). Fever episodes can be triggered by minor
infections, physical and emotional stress, and childhood immunizations. However, most
attacks occur without a clear precipitating event (5). Inflammation in MA may be more severe
since it had been fatal in some cases (6). In addition to the fever episodes, MA patients have
variable degrees of psychomotor retardation, facial dysmorphy, failure to thrive,
hepatosplenomegaly, and anemia (5;6).
In MA, MK enzyme activity in patient cells is usually virtually undetectable (6;7). In HIDS,
however, residual MK activity is measurable, and varies between 1% and 7% in cultured skin
fibroblasts and lymphocytes (3;8). MK deficiency in both MA and HIDS is caused by
mutations in the MVK gene which encodes MK (2-4;7-11). One particular missense mutation
has been identified exclusively in HIDS. This mutation, 1129 G>A, leads to the substitution
of the valine at position 377 for an isoleucine (V377I) and has been found in ~90% of HIDS
patients analyzed so far (8;11). Most HIDS patients are compound heterozygotes for this
mutation and a second missense mutation. The second mutation often is one that has been
identified also in MA, implying that it results in a non-functional enzyme. This indicates that
the V377I substitution is responsible for the HIDS phenotype.
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It is unclear how mevalonate kinase deficiency leads to inflammation. Neither is it clear, why
this inflammation is episodic rather than continuous. Previously, we and others demonstrated
that heterologous expression of the V377I mutant MK protein in Escherichia coli yielded
considerable residual enzyme activity (3;12). In contrast, cultured human skin fibroblasts
homozygous for this mutation showed less than 8% residual enzyme activity. Furthermore,
upon immunoblotting, hardly any MK protein could be detected (3), while Northern blot
analysis demonstrated that this was not due to lowered MVK gene expression (8). Together,
this suggested that the V377I mutation affects the stability and/or maturation of the mutant
MK.
We now report that the common V377I mutation and a second mutation found in a patient
with HIDS indeed affect the stability and/or maturation of MK in patient cells in a
temperature sensitive manner. The decrease in MK activity occurring at elevated temperatures
may provide an explanation for the episodic nature of the fever episodes in HIDS.
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Patients and Methods
Patient cell lines and cells
After approval by the institutional ethical review board and written informed consent by the
patients’ parents, skin fibroblasts were obtained by skin biopsy and/or blood was drawn by
venipuncture in sterile pyrogen-free heparinized plastic tubes. Peripheral blood mononuclear
cells (PBMC) were isolated by ficoll hypaque (Amersham Pharmacia Biotech, Uppsala,
Sweden) density gradient centrifugation, washed twice with PBS, snap frozen in liquid
nitrogen in aliquots of 3-10 x106 PBMC and stored at –80ºC until assay.
Fibroblast cell lines were cultured in Nutrient Mixture Ham’s F-10 with L-glutamine and 25
mM HEPES (Gibco, Invitrogen, Carlsbad, CA) supplemented with 10% Fetal Calf Serum
(Gibco) at the temperatures indicated. For enzyme and immunoblot analysis cells were
harvested and washed twice with phosphate buffered saline (PBS) after trypsinization, and
either used directly or snap-frozen in liquid nitrogen and stored at –80ºC until use.
All patients and patient cell lines had low MK enzyme activity in combination with mutations
in the encoding MVK gene.
MK and 3-hydroxy-3-methylglutaryl-CoA reductase enzyme analysis
MK activity was measured radiochemically in cell lysates using 14C-labelled mevalonate
(NEN, Perkin Elmer Life Sciences, Boston, MA)(13). 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGR) was measured radiochemically in cell lysates using 14C-labelled 3-
hydroxy-3-methylglutaryl-CoA (Amersham Pharmacia Biotech, HMG-CoA)(14). When
necessary, the obtained batch of 14C-HMG-CoA was further purified by cellulose thin layer
chromatography using as solvent system 1-butanol : acetic acid : water (5 : 2 : 3). Cell pellets
were lysed by sonication (twice, 40 J at 8 W output, with cooling between the pulse periods).
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This was done in PBS when only MK was assayed or in HMGR assay buffer (14) when both
HMGR and MK were measured simultaneously. In the latter case, extra MgCl2 (12.7 mM
instead of 6 mM) was added to assay MK in order to compensate for the EDTA and EGTA
present in the HMGR assay buffer. The thermal inactivation experiments were performed in
PBS containing 10 mM dithiothreitol (DTT) in order to prevent inactivation of MK due to
oxidation (15). Samples were removed on time points indicated and assayed for activity. In
every sample the activity of MK and/or HMGR was determined in duplicate.
Immunoblot analysis
Immunoblot analysis was performed in the same samples used for MK enzyme analysis.
Antibodies were generated as described in Hogenboom et al. (14). Detection by
chemiluminescence was performed using the Western Light system (Tropix, Applied
Biosystems, Foster City, CA) or the enhanced chemiluminescence kit (ECL, Amersham
Pharmacia Biotech).
Statistical methods
The medians were compared by either an unpaired two tailed Mann-Whitney test, or a
Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s multiple comparisons test. A
p-value<0.05 was considered significant. The mean values are displayed ± the standard
deviation.
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Results
The V377I mutation affects MK activity in a temperature sensitive manner
Since episodic fever is a prominent symptom of HIDS and MA, we studied whether
temperature has an effect on MK enzyme activity. To this end, skin fibroblast cell lines of
control subjects, MA and HIDS patients with different genotypes were cultured at 30°C, 37°C
or 40°C for 3 days. The HIDS cell lines used for this study were from patients which are
compound heterozygous for the V377I and either the H20P mutation or the I268T mutation.
The H20P mutation has been shown to result in an unstable and fully inactive protein and the
I268T mutation in homozygous state results in MA (7;9). The MA cell lines were from
patients which are homozygous for the I268T and for a V310M mutation and compound
heterozygous for a H20P and an A334T mutation (7;9;10). Enzyme analysis in the various
cell lines revealed that the residual MK enzyme activity in the HIDS cells cultured at 37°C
varied between 1.1% and 3.0%, whereas the residual activity in the MA cells was virtually
undetectable (figure 1). When the same cells were cultured at 30°C, the residual MK enzyme
activity in the HIDS cells increased up to 9%, whereas the activity in these cells grown at
40°C became virtually undetectable. No change in the residual MK enzyme activities in the
MA cells was detected. Although the MK activity in the control cells also increased at 30°C
and decreased at 40°C, these differences were smaller than in the HIDS cell lines.
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FIG. 1. Relative enzyme activities of MK in fibroblast lysates and immunoblot analysis of
MK in the corresponding samples after 3 days of culture at the indicated temperature. The
specific activity of the control fibroblast cell line grown at 37°C (598 pmol/min/mg protein) is
used as the 100% value. For immunoblot analysis, equal amounts of protein (45 µg) were
separated by 10% SDS-PAGE and analyzed on immunoblot with MK-specific antibodies. As
a control for equal loading, the blot was analyzed with actin-specific antibodies. The figure
includes a control cell line (C), two MA cell lines (M1, I268T; M2, V310M) and three HIDS
cell lines (H1, H20P/V377I; H2, H20P/V377I; H3, H20P/V377I). The results for the HIDS
and MA cell line with the I268T/V377I and H20P/A334T genotypes are not shown.
Houten / Frenkel: Temperature affects MK activity in HIDS 10
To determine whether the increase in MK activity at lower temperatures is due to an increase
in MK protein levels we performed immunoblot analysis with an MK-specific antibody
(figure 1). This revealed that immunoreactive material in lysates of the HIDS cells grown at
30°C becomes readily detectable, while hardly any MK protein is detected in HIDS cells
grown at 37°C. When grown at 40°C immunoreactive material is undetectable (figure 1). MK
protein levels in the MA cells are very low but detectable and do not change with
temperature. Taken together, these results indicate that all mutations tested result in unstable
proteins with very low steady-state levels of active and properly folded MK protein. In the
case of the V377I allele, however, the levels appear to be dependent on the culturing
temperature.
To study this phenomenon in more detail, we transferred control, HIDS (H20P, V377I) and
MA (I268T) fibroblast cell lines from 37°C to 30°C and measured MK activity after 24, 48,
96 and 144 hours of culture. Again the activity of MK in the MA cell line remained virtually
undetectable at all time points, whereas the activity in the HIDS cell line increased to even
45% after 144 hours (figure 2a). Since this HIDS cell line is heterozygous for the V377I allele
and the fully inactive H20P allele, enzyme activity is expected to increase no further than
50%. These results imply that the V377I allele produces a fully stable protein at 30°C.
To study the stability of the matured enzymes, we performed thermal inactivation
experiments with MK in control and HIDS fibroblast lysates at 50°C and 37°C. The
inactivation process followed first order kinetics and was significantly faster in HIDS cell
lysates at both temperatures, although the difference was only 1.3-fold (p<0.05, figure 2b and
2c). This shows that the mutant V377I protein, after it has reached the active and properly
folded conformation, is almost as stable as the WT protein. Moreover, it shows that the V377I
mutation primarily affects its maturation and not the stability per se.
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Figure 2a
Figure 2b
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Figure 2c
FIG. 2. a. Relative enzyme activities in fibroblast lysates of control, HIDS (H20P/V377I) and
MA (I268T) cell lines after the indicated time grown at 30°C. The specific activity of the WT
cell line after 1 day at 30°C (349 pmol/min/mg protein) is used as the 100% value. b. Thermal
inactivation of MK enzyme activity in WT and HIDS cell lysates at 50°C. c. Thermal
inactivation of MK enzyme activity in WT and HIDS cell lysates at 37°C.
Temperature sensitivity in another HIDS causing mutation
Although the vast majority of HIDS patients carry the V377I allele, at least three additional
mutations appear specific for HIDS as well: A148T (442 G>A), P167L (500 C>T), and
T209A (625 A>G)(2;3;8;16). In order to study whether temperature sensitivity of the MK
protein could be a common characteristic for HIDS, we tested a cell line heterozygous for the
A148T allele and the I268T allele (8). To this end, this cell line, a control cell line and a
HIDS cell line containing the V377I allele were cultured at 30°C and 37°C for 6 days.
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Residual activity of MK in the HIDS cell line containing the V377I increased 9-fold, and in
the HIDS cell line with the A148T mutation the residual activity increased 8-fold, which
indicates that the two mutant alleles produce MKs with similar temperature sensitivity (figure
3).
FIG. 3. Relative enzyme activities of one control, one HIDS cell line with V377I
(H20P/V377I) and one HIDS cell line without V377I (A148T/I268T) after 6 days of culture
at 30°C. The specific activity of the control fibroblast cell line grown at 37°C (543
pmol/min/mg protein) is used as the 100% value.
Temperature elevation induces increased HMGR activity in HIDS fibroblasts
Table 1. HMGR enzyme activity in fibroblasts and PBMCs from controls subjects, HIDS and
MA patients.
Fibroblasts PBMCs
Controls 5±2 (24; 5) 2±1 (20; 10)
HIDS 7±4$ (19; 7) 12±4*** (15; 7)
MA 73±46*** (26; 5) 40 (1; 1)
Values are expressed as pmol/min.mg protein.
$p=0.5, ns
***p<0.001
The number of samples and different subjects, respectively, are displayed in parentheses.
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HMGR is among the most tightly regulated enzymes in nature and is the rate-limiting enzyme
step in isoprenoid biosynthesis (17). As previously reported by Gibson et al. (18), we
observed an increased HMGR activity in cultured skin fibroblasts of MA patients (table 1). In
fibroblasts of HIDS patients, however, HMGR activity was within the normal range. Since we
found that MK activity is temperature-sensitive in HIDS cells, we investigated whether an
increased temperature induces an increase in HMGR activity. Indeed, when switched to 39°C
a marked difference between HIDS and control fibroblasts was observed (table 2).
Table 2. MK activity, HMGR activity and the MK/HMGR ratio in
fibroblasts of control and HIDS patients cultured at different
temperatures.
Subject Condition MK
pmol/min.mg
HMGR
pmol/min.mg
MK/HMGR
C1 37°C 394±14.9 6±0.1 64
C1 39°C, 6h 347±10.0 6±0.1 59
C1 39°C, 23h 313±2.4 7±0.4 43
C2 37°C 343±38.8 4±0.4 77
C2 39°C, 7h 311±11.2 4±0.5 87
C2 39°C, 25h 274±6.0 6±0.5 48
C2 37°C 357±20.0 6±1.6 57
C2 39°C, 7h 310±7.8 6±0.5 51
C2 39°C, 24h 288±2.4 11±1.0 27
H1 37°C 19±1.2 7±0.4 2,6
H1 39°C, 6h 9 12±1.6 0,72
H1 39°C, 23h 7±0.9 15±0.3 0,47
H2 37°C 22±0.8 8±0.5 2,7
H2 39°C, 6h 11±0.1 13±0.0 0,87
H2 39°C, 23h 10±0.3 26±2.2 0,39
H3 37°C 21±0.6 4±0.5 4.7
H3 39°C, 7h 11±0.2 4±0.5 2.4
H3 39°C, 25h 4±0.5 9±0.2 0.46
H4 37°C 44±0.6 10±1.0 4.3
H4 39°C, 7h 15±0.3 19±0.7 0.77
H4 39°C, 24h 22±0.9 13±0.3 1.62
The presented data in the table are derived from three independent
experiments. The control cell lines are denoted as C, the HIDS cell lines
as H1 (I268T/V377I), H2 (H20P/V377I), H3 (H20P/V377I) and H4
(I268T/V377I).
After 6 hours there was a decrease in MK activity and an increase in HMGR activity in most
HIDS cells, whereas this did not occur in control cells. After 24 hours this effect was even
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more pronounced, which is reflected clearly in the 4 to 7-fold decrease in MK/HMGR ratio
(table 2).
FIG. 4. A fever episode in a HIDS patient (I268T/V377I). The figure displays body
temperature, MK activity, C-reactive protein (CRP) and absolute neutrophil count (ANC) at
the indicated time-points during the fever episode.
Houten / Frenkel: Temperature affects MK activity in HIDS 16
Decrease of MK activity in HIDS PBMCs during fever
To investigate whether temperature also affects in vivo MK activity in patients, we analyzed
MK and HMGR activity in PBMCs obtained from four HIDS patients during and between
fever attacks. From HIDS patient A (table 3, figure 4), we obtained PBMCs on the first and
second day of a fever attack and twice after recovery. The generalized inflammation during
the fever attack was reflected by neutrophil leukocytosis and elevated C-reactive protein
(CRP) levels. We measured MK and HMGR activity in all samples. As shown in figure 4, in
this patient the MK activity of ~14 pmol/min.mg (6% of the control value) between fever
episodes decreases 3-fold during fever (~5 pmol/min.mg). In patient B and patient C the drop
in MK activity during fever was even higher: six- and seven-fold respectively. Finally, in one
clinically severely affected patient, MK activity showed no response to the fever and
remained low whether or not fever was present. Overall, in the 4 HIDS patients, MK activity
during fever episodes was significantly lower than at normal temperature (p<0.05).
In general, the HMGR activities measured in the PBMCs from the HIDS patients appeared
significantly elevated compared to controls, although less than in PBMCs of an MA patient.
Analysis of the HMGR enzyme activity in the samples obtained from the four HIDS patients
during and between fever attacks revealed a 2-fold rise in HMGR activity during fever in
patients B and C, whereas in patients A and D there was only a modest response to fever or
none at all. Thus, the patients who showed the most pronounced difference in MK activity
also displayed the greatest difference in HMGR enzyme activity. Overall, however, the
difference between HMGR activity during and between fever episodes was not significant
(p<0.1).
Taken together, these results indicate that although MK activity is lowered at all times in
PBMCs from HIDS patients, this deficiency becomes more prominent during fever.
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Table 3. MK activity, HMGR activity and the MK/HMGR ratio in
PBMCs of HIDS patients during and in between fever episodes.
Patient Condition MK
pmol/min.mg
HMGR
pmol/min.mg
MK/HMGR
A Fever 5 12 0.38
A Non febrile 14 15 0.95
B Fever 1 20 0.07
B Non febrile 6 8 0.74
C Fever 1 16 0.07
C Non febrile 7 9 0.82
D Fever 2 14 0.12
D Non febrile 3 9 0.31
The mean MK and HMGR values in controls are 217±51 and 2±1
pmol/min.mg, respectively. All patients had the same genotype,
I268T/V377I.
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Discussion
Three years after the identification of the genetic defect in HIDS, the pathogenesis of the
fever attacks that characterize the disease remains elusive. It is not known how the metabolic
defect leads to inflammation. Neither is it known why inflammation is episodic rather than
continuous. Patients often report attacks after trivial events such as minor infections,
vaccinations or vigorous exercise, events that also in otherwise healthy individuals
temporarily raise body temperature. We hypothesized that such an increase in temperature
may be involved in triggering the attacks. Since most MVK mutations result in deficient MK
activity mainly due to reduced protein levels, we studied the effect of changes in temperature
on the activity of normal and mutant mevalonate kinase.
We found that two MVK alleles exclusively associated with HIDS (V377I and A148T)
display temperature sensitivity with respect to MK activity. For mutant alleles found in MA
we did not observe such temperature sensitivity. When grown at 30°C the residual MK
activity in cultured HIDS fibroblasts increases much more than in control cells, whereas at
40°C the residual activity diminishes. Importantly, this change in enzyme-activity correlates
nicely with similar changes in the MK protein-levels as determined by immunoblotting. Since
thermal inactivation of the mutant MK protein appears comparable with the WT protein, the
observed low steady-state protein level in cells of HIDS patients is most probably due to
inefficient or incorrect folding of the mutant protein at 37°C leading to its degradation.
Recently, Ríos et al (12) characterized the V377I mutant protein expressed in E. coli. They
found only modest kinetic differences in comparison with the WT enzyme (6-fold inflation of
the Km for mevalonate) and, as we did in patient fibroblast cell lines, normal thermal
inactivation of the mutant protein. From these results these authors concluded that the V377I
mutation is unlikely to provide an explanation for the observed depressed MK protein levels
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and catalytic activity in HIDS. However, our results with the fibroblast lysates show that the
V377I allele encodes a polypeptide that apparently is not capable of folding in the correct
conformation at higher temperatures and subsequently undergoes degradation. These results
together with all the genetic evidence such as the occurrence of this specific mutation in the
vast majority of HIDS patients (8;11), its absence in control subjects (2), the results of linkage
analysis (2) and the autosomal recessive mode of inheritance, unequivocally demonstrate that
the V377I allele is the cause of the depressed MK activity in HIDS.
When we measured HMGR enzyme activity in cultured HIDS and MA fibroblasts, we found
the activity elevated in MA fibroblasts as previously reported by Gibson at al. (18), whereas
in HIDS cells, it was within the normal range. These results indicate that under the tested
culture conditions MA cells compensate for their reduced MK activity, whereas in HIDS cells
no compensation occurs. When HIDS fibroblasts are cultured at 39°C, however, the decrease
in the enzymatic activity of MK is associated with an increased HMGR activity, in contrast to
the control cells. This indicates that due to the increase in culture temperature MK becomes
progressively rate-limiting, resulting in an increased HMGR enzyme activity in order to
compensate for the decrease in MK activity. These results thus provide an explanation for the
observed increase in mevalonate excretion during fever episodes in HIDS (19). Together with
the reported difference in mevalonate excretion in urine between HIDS and MA (3;6;19),
these observations also imply that in MA, MK performs the rate-limiting step instead of
HMGR, whereas in HIDS the control of the pathway, at least at normal temperatures, remains
at the level of HMGR.
We investigated whether the thermosensitivity of MK activity observed in vitro also plays a
role in HIDS patients during and between fever episodes. Therefore we analyzed MK and
HMGR activity in PBMCs obtained from four HIDS patients during and between fever
attacks. We observed that MK enzyme activity drops 2-6-fold when HIDS patients experience
Houten / Frenkel: Temperature affects MK activity in HIDS 20
febrile attacks. In contrast to the normal HMGR enzyme activity in fibroblasts from HIDS
patients, we observed an elevated HMGR enzyme activity in PBMCs from these patients.
Although this elevation was not as high as in a sample obtained from an MA patient, it
indicates that there is a derangement in isoprenoid biosynthesis in PBMCs from HIDS
patients. No significant difference was observed in HMGR enzyme activity during and
between a fever episode. However, the two patients who showed the most pronounced
difference in MK activity also displayed an additional elevation in HMGR enzyme activity
during fever. This could suggest that an elevation in HMGR enzyme activity may be missed
in the other patients due to a delay between the onset of the attack and sampling. Our results
show that during fever, MK deficiency in PBMCs from HIDS patients becomes even more
prominent. From our in vitro data we conclude that this is caused by the impaired maturation
of MK especially at higher temperatures.
There are several indications that isoprenoid biosynthesis plays a role in inflammation. For
example, it has been reported that administration of LPS, TNF-α, or IL-1β to Syrian hamsters
triggers a rapid upregulation of hepatic HMGR and a downregulation of squalene synthase,
the enzyme catalyzing the first committed enzyme step of sterol biosynthesis (20-22). These
observations suggest a higher demand for non-sterol isoprenoids during inflammation.
Examples of non-sterol isoprenoids are the farnesyl- and geranylgeranyl-groups used for
protein isoprenylation, isopentenyl tRNAs, dolichol, ubiquinone-10, and heme A.
Furthermore, statins, a class of lipid-lowering drugs that are competitive inhibitors of HMGR
and accordingly lead to decreased production of isoprenoids, have been reported to have both
anti-inflammatory (23-26) and pro-inflammatory effects (27-29). Our data reported here
suggest that in HIDS patients, the fever which accompanies inflammation enhances the MK
deficiency, which will result in a temporary reduction in non-sterol isoprenoid production.
This will affect especially isoprenoids with a high turnover, such as ubiquinone-10 in plasma,
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which is decreased in most MA patients(30), prenylated small G-proteins like Rho (31),
which are involved in multiple cellular processes like signal transduction or cytoskeletal
organization, and the prenylated guanylate-binding proteins (GBP) which are specifically
synthesized in response to IFN-γ and LPS (32). It is conceivable that this shortage of non-
sterol isoprenoids is responsible for the pro-inflammatory phenotype of HIDS and MA. Thus,
even minor elevations in temperature, due to exercise or infections could set off a chain of
events, with MK becoming progressively rate limiting, leading to a temporary deficiency of
anti-inflammatory isoprenoids, followed by inflammation and fever.
Strong support for this hypothesis is provided by the negative outcome of a therapeutic trial in
which two MA patients were treated with low doses of lovastatin in order to block the
production of mevalonate (speculated to be pathogenic). This trial had to be stopped because
of the development of severe clinical crises (6). The outcome of this trial strongly suggests
that the symptoms of MA are not caused by an excess of mevalonate but by a shortage of
isoprenoid endproducts. The enormous difference in urinary mevalonate excretion in HIDS
and MA patients also argues against a causative role of mevalonate in the pathogenesis of the
clinical crises. MA patients have much higher mevalonate levels, but fever episodes occur as
frequently as in HIDS.
The observed differences in stability and temperature sensitivity of mutant MKs may explain
why HIDS patients display episodic fever. Since such fever episodes are prominent not only
in HIDS but also in MA, the same may be true for MA. Indeed, the fact that mevalonate
excretion in urine of both HIDS and MA patients correlates with disease severity points to a
similar mechanism (6;19). Unfortunately, the extremely low and already hardly detectable
MK activity levels in MA cells do not allow to demonstrate a similar temperature sensitive
phenomenon. However, the finding that the increase in temperature does not only affect the
mutant MKs, but also the wild-type MK activity makes it highly plausible. Even a small
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additional decrease in the already extremely low MK activity in MA cells may have far
reaching consequences. Since HMGR already appears maximally induced to compensate for
the MK deficiency, a further induction to establish even higher mevalonate levels may not be
possible. Furthermore, in MA cells the MK enzyme will be saturated already, thus an
additional increase in the mevalonate concentration will have no effect on the flux through the
pathway. These reasons may provide an explanation for the reported fatal outcome of a fever
episode in several MA patients (6).
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Summary and general discussion
Since its initial recognition by van der Meer nearly 20 years ago(1), much has been
learned about the Hyper IgD and Periodic fever syndrome (HIDS) or Dutch periodic
fever (DPF) (MIM#260920). The clinical features of the disease have been analyzed
in detail (2). The three cardinal features of the syndrome, the raised IgD and IgA, the
generalized inflammation, leading to high fever, and the discontinuity of clinical
symptoms remained largely unexplained and effective treatment has remained elusive.
Studies into the inflammatory effector mechanisms involved, identified increased
activity of pro-inflammatory cytokines, such as Interferon (IFN)-γ, Tumor Necrosis
Factor (TNF)-α, Interleukin (IL)-1β and IL-6 (3-7).
Figure 1
Understanding of the pathogenesis of HIDS in 1999
In 1999, it became clear that mevalonate kinase deficiency could lead to HIDS (8;9).
The unexpected finding of an inborn error of metabolism at the root of this
inflammatory disease generated at least as many questions as answers (fig. 1)(10). To
name just a few, what exactly is the relation between mevalonate kinase deficiency
and HIDS?
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• Do all patients diagnosed with HIDS have mevalonate kinase deficiency?
• What causes some cases of mevalonate kinase deficiency to present with the
HIDS phenotype and others with the more severe mevalonic aciduria
phenotype?
• How does mevalonate kinase deficiency give rise to inflammation? Is this due
to excess of its substrate (mevalonate) or shortage of one of the many products
of isoprenoid biosynthesis (fig.2)?
• In which cells or which tissue(s) does this metabolic deregulation have its
inflammatory effect?
• What other inflammatory effector mechanisms are involved?
• And how can we explain that a continuous metabolic defect leads to episodic
disease. These were the questions that we attempted to address in this study.
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Figure 2
Schematic representation of isoprenoid biosynthesis pathway.
In chapter 2, we studied a group of children with HIDS(11). It turned out that not all
HIDS patients have mevalonate kinase deficiency. Indeed, entirely normal
mevalonate kinase activities were found in about 20% of all patients. This finding has
now been confirmed in adult patients as well (12). Hence, HIDS is a phenotype of
mevalonate kinase deficiency, but patients with the HIDS phenotype, without the
mutant MVK genotype, are not rare. However, some features, such as onset in infancy,
prominent skin rash and diarrhea, appear more common in the DPF- or true HIDS-
patients, i.e. those with mevalonate kinase deficiency. Elevated serum IgD has been
reported to occur in all the other known hereditary periodic fever syndromes, as well
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as in the periodic fever- aphtous stomatitis pharyngitis adenitis (PFAPA) syndrome
(13-15). It might well be present in other, as yet unrecognized periodic fever
syndromes. However, what is unusual about the DPF or true HIDS, as it has been
called, is that hyperimmunoglobulinemia D is so extremely common. It is presently
unknown how this rise in IgD is caused. Eventual unraveling of its mechanism should
provide valuable insight in the relation between isoprenoid biosynthesis and the
immune system. The physiological function of serum IgD is not known nor is its role
in HIDS (16). However, HIDS patients may initially have normal serum IgD values
(17), and in some patients IgD will remain normal throughout (8). High IgD,
therefore, is unlikely to have an important role in the causation of inflammation. The
finding of mevalonate kinase deficient patients with normal IgD and of HIDS patients
with normal mevalonate kinase creates a semantic problem. The name by which the
disease is identified in the On-line Mendelian Inheritance In Man (OMIM), Dutch
type Periodic Fever, obviates this problem. However, this ignores the fact that many
patients are not of Dutch descent (18). The nomenclature, therefore, remains a
practical issue that needs to be solved.
Not all patients with mevalonate kinase deficiency present with HIDS. So much
already followed from the finding of patients who were clinically and biochemically
indistinguishable from HIDS, but had normal serum IgD (8). Furthermore there are
two phenotypes of mevalonate kinase deficiency: HIDS and Mevalonic Aciduria. The
latter is akin to HIDS in that patients suffer from recurrent inflammatory attacks. In
addition, affected children may have various other problems. Commonly, MA patients
are born small for gestational age. They grow poorly and their neurological
development is usually impaired. Moreover their faces often show dysmorphic
features (19). In chapter 3 we show that unique mutations are involved in HIDS as
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opposed to MA (20). All HIDS patients studied, had at least one copy of the MVK-
gene that carried the 1129 G>A mutation coding for the amino acid substitution
V377I. None of the MA patients studied had this mutation. The V377I mutant protein
leads to a less profound MK deficiency than the mutations encountered in MA. It is
this mild MK deficiency that appears to give rise to the HIDS phenotype. The
distinction between the MA phenotype and the HIDS phenotype may however be less
absolute than suggested here. In one family with HIDS, the two affected members
(No’s 15 and 16 in the international HIDS registry) are severely mentally retarded,
despite being compound heterozygote for the mutations V377I and W62X and having
1.4% residual MK activity. Moreover, high IgD has been described in a mevalonic
aciduria patient(21), indicating that the HIDS and MA phenotypes are the extremes of
a continuous clinical spectrum. The rarity of patients, homozygous for V377I was
striking in face of the frequency of this allele in compound heterozygotes. This
suggests that individuals homozygous for V377I, are not being identified.
Theoretically this could be due to intrauterine death of V377I homozygotes. This,
however, is unlikely, since their defect is presumably milder than that in the
compound heterozygotes who do in fact come to our attention. More likely, the
V377I/V377I phenotype may in many instances be very mild or even asymptomatic.
The genotype-phenotype relation in HIDS and mevalonate kinase deficiency,
therefore, remains complex (fig.3).
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Figure 3
Diagram of the disease entities relevant to mevalonate kinase deficiency and periodic
fever. MA: mevalonic aciduria, HIDS: HyperIgD and periodic fever Syndrome, DPF:
Dutch type Periodic Fever, MKD: mevalonate kinase deficiency.
This complex genotype-phenotype relation inevitably has consequences for the
diagnostic approach of the child with unexplained recurrent fever in general and of
periodic fever due to mevalonate kinase deficiency in particular. The gold standard
for the latter diagnosis is the demonstration of disease causing mutations in both
MVK-alleles. When new mutations are found, measuring MK activity will be
necessary to distinguish between true mutations and polymorphisms. Several
diagnostic tests have been employed to diagnose true HIDS, notably, the serum IgD
concentration and the urinary excretion of mevalonic acid. However, the performance
of these test, i.e. their positive and negative predictive value, has not been formally
evaluated. Preliminary data indicate, that, when first evaluated, less than half of the
MK deficient children in our hospital had a serum IgD level exceeding the adult upper
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limit of normal, 100 IU/ml. Age specific normal values for serum IgD have been
reported to lead to an increased sensitivity (22). However, when applied to our
population, the initial IgD measurement would have been elevated in only 45 % of
MK deficient children. On repeated testing, this figure eventually does rise to 85%.
The specificity of a repeatedly elevated serum IgD concentration does appear to be
better with the application of age specific reference values instead of those for adults.
However, these pediatric normal values have been collected in healthy Icelandic
children, whereas, in clinical practice, the patient to be investigated has recurrent
fever and is not Icelandic, for which case normal values are not available. Another
problem is the interpretation of the urinary excretion of mevalonic acid. Mild
elevations of urinary mevalonic acid and the corresponding lactone have been
observed in all patients with mevalonate kinase deficiency (8;23;24). However,
especially between febrile attacks, these levels may overlap with those observed in
pediatric patients with children with inflammatory disorders and normal mevalonate
kinase activities. Apparently, the normal values, obtained in healthy persons do not
fully apply to these children. Clearly, additional studies are required to establish the
value of urinary mevalonic acid measurement as a tool for the diagnosis of HIDS
Measuring mevalonate kinase activity in patients’ cells is feasible in expert
laboratories. False positive results (i.e. deficient MK activities) have been obtained
when studying leukocytes, whereas this is less likely to happen in cultured skin
fibroblasts (Sander M.Houten, personal observation)
We therefore suggest that in children with a history, typical of HIDS, including onset
in infancy, fever following vaccinations, lymphadenopathy and skin rash, genetic
testing for MVK-mutations is performed, irrespective of serum IgD values. When
feasible, this should be preceded by the assay of MK enzyme activity. In patients with
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a less typical clinical presentation, the repeated finding of serum IgD over the 95th
percentile for age should prompt MVK mutation analysis, again, preferably in
conjunction with MK enzyme activity measurement.
This approach can teach us that periodic fever in an individual patient is due to
mevalonate kinase deficiency. However, how this defect leads to fever remains
elusive. Mevalonate kinase deficiency leads both to reduced production of isoprenoids
(fig.2) and accumulation of mevalonic acid. The question which of these two
phenomena gives rise to inflammation is addressed in chapter 4. In an ex-vivo model,
we measured IL-1β secretion by isolated mononuclear cells in response to T-cell
stimuli. In this model, reducing isoprenoid production led to a rise in IL-1β secretion,
whereas the addition of mevalonate had no such effect. Similar observations have
now been made by Kiener et al., when studying isolated normal monocytes treated
with lovastatin and other lipophilic statin drugs (25). Therefore, it is unlikely that
excess mevalonate is responsible for the inflammation in HIDS. Furthermore, the IL-
1β secretion by HIDS cells could be reduced by the addition of farnesol, a precursor
of isoprenoid synthesis, downstream of the defect in mevalonate kinase. Interestingly,
varying the availability of mevalonate to cells from HIDS patients, had a profound
effect on the IL-1β secretion by these cells. When mevalonate was reduced through
the action of lovastatin, IL-1β secretion rose, whereas the addition of mevalonate led
to a decrease in IL-1β secretion. These findings are in keeping with those of Houten et
al, who demonstrated that protein isoprenylation in fibroblasts from HIDS patients
was uniquely dependent on the availability of mevalonate. It follows that treatment of
mevalonate kinase deficiency should focus on the restoration of isoprenoid
biosynthesis, rather than on the inhibition of mevalonate production. If inflammation
indeed results from a shortage of one or more of the many products of isoprenoid
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biosynthesis, it still is unclear which product it could be and how it would normally
act. Cholesterol and its derivatives are unlikely candidates, since inflammation is no
feature of the inborn errors affecting the terminal steps of cholesterol biosynthesis
(24). Furthermore, the studies performed in isolated monocytes by Kiener et al
implicated shortage of non-sterol isoprenoids in the secretion of pro-inflammatory
cytokines(25). Non-sterol isoprenoids are compounds such as presqualene
diphosphate and a number of isoprenoid groups, which are normally attached to
specific macromolecules. These are the isopentenyl groups of isopentenyl t-RNA’s,
dolichol, the polyisoprene groups of Heme-A and ubiquinone-10, and the
geranylgeranyl- and farnesyl-groups, involved in post-translational protein
modification. Examples of proteins that are geranylgeranylated are the Rho, Rac and
Cdc42 molecules, involved in leukocyte activation and migration and the Rab
molecules, involved in vesicle transport and exocytosis. The best known farnesylated
proteins are molecules from the Ras- family, involved in cell proliferation. Whichever
of these compounds is deficient in HIDS, any attempted therapy should aim at
restoration of this deficit. To this end, two approaches could be envisaged. The first
would be to increase the availability of mevalonate through up regulation of 3-
hydroxy-3-methylglutaryl- (HMG-)CoA reductase. The synthesis of HMG-CoA
reductase mRNA and the half life of the HMG-CoA reductase protein is known to
increase in response to lowering intracellular cholesterol (26). This could be
accomplished by elimination of dietary cholesterol and by means of treatment with
oral bile acid sequestrant resins. These drugs deplete the bile acid pool. Consequently,
cellular cholesterol is siphoned off into bile acid biosynthesis. The resulting increase
in HMG-CoA reductase activity will restore cholesterol biosynthesis. It is, however,
uncertain at best, whether it would lead to the restoration of non-sterol isoprenoid
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levels. The second approach would entail the suppletion of mevalonate or isoprenoid
intermediary metabolites, such as isopentenyl pyrophosphate, geranyl pyrophosphate,
farnesyl pyrophosphate. The corresponding fatty alcohols might be useful pro-drugs
in this respect. However, there are safety concerns regarding both approaches.
Extreme cholesterol depletion, as would result from the combination of mevalonate
kinase deficiency, dietary restriction and draining the bile acid pool, might
theoretically carry the risk of myopathy or even rhabdomyolysis, since myopathy is a
feature of both mevalonic aciduria and statin drug toxicity. As for treatment with
isoprenoid fatty alcohols, there is no clinical experience whatsoever with these
compounds. Indeed, feeding metabolites into a pathway that is normally very tightly
regulated could have many untoward effects. Therefore these approaches should be
tested in the animal model first. To this end, the generation, by site directed
mutagenesis, of mevalonate kinase deficient mice is vital.
From the previous it appears that decreased biosynthesis of non-sterol isoprenoids and
inflammation are linked. Non-sterol isoprenoids are essentially intracellular
molecules. Hence, there must be cells in which the disturbed isoprenoid biosynthesis
leads to loss of control of inflammatory activation of that same cell. We therefore had
to know, which cell population was activated in HIDS.
In chapter 5 we studied leukocytes from HIDS patients during and between fever
attacks. Several leukocyte subsets, could be expected to be activated in this disorder.
B-lymphocytes might be involved, as suggested by the polyclonal elevation of IgD
and IgA, typical of HIDS (27). T-lymphocytes, had been implicated previously,
because of the high serum concentrations of IFN-γ during fever attacks (5). Cells of
the monocyte/macrophage lineage were expected to be activated. Inflammatory
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mediators typically produced by such cells, have been found to be secreted in
increased amounts either in-vivo, ex-vivo or both (6;7). Also, the raised urinary
neopterin (7) and Leukotriene E4 excretion (chapter 5) is indicative of activation of
mononuclear phagocytes. Finally, neutrophil granulocytes could be involved, since
granulocytosis is a well known feature of the fever attacks in mevalonate kinase
deficiency (2). Though discrete signs of T-cell activation were detectable, the most
striking changes were observed among myeloid cells. There was a 4-fold increase in
the number of neutrophil granulocytes and a 3-fold rise in monocyte numbers.
Moreover, these cells were activated, as reflected by the raised expression of CD64.
It can not be excluded, that these myeloid cells are activated indirectly by some other
cell population. It is conceivable that T-lymphocytes are involved in the initiation of
the fever episodes, since these attacks are often triggered by immunizations or
infections and the serum concentration of T-cell derived cytokines is elevated in
HIDS. Also, the activation of non-circulating cells, such as sessile macrophages or
dendritic cells would not have been detected by the present study, whereas the
enlargement of lymph nodes, liver and spleen during fever attacks in HIDS would be
compatible with the involvement of such cells.
However, the analogy with the other hereditary periodic fever syndromes would favor
a central role for granulocytes and monocytes. We speculate that it is in these myeloid
cells, that the metabolic defect interferes with some, as yet unidentified, anti-
inflammatory pathway. This anti inflammatory pathway might involve the apoptosis
of activated granulocytes and monocytes, since the genes mutated in hereditary
periodic fever syndromes other than HIDS all encode proteins presumed to play a role
in apoptosis (28). The sequence of events would then be, that these cells are triggered,
e.g. via T-cell activation, after which inflammatory activation runs out of control.
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From the point of view of treatment, given the limitations of approaches aimed at
increasing isoprenoid biosynthesis, non-specific inhibition of neutrophil and
monocyte/macrophage activation would be an attractive option. However, experience
with drugs that act in this fashion has been disappointing. Glucocorticoids, colchicine
and thalidomide have all met with limited success (2;29). Biological agents,
interfering with the soluble mediators produce by monocytes/macrophages do hold
promise, however. Limited experience with etanercept, a fusion protein of the Fcγ and
the ligand binding domains of the TNF receptor TNFRSF1B, has been encouraging.
Similar “biologicals” have been developed which antagonize the actions of IL-1 (IL-
1-receptor antagonist, anakinra) or IL-6(30;31). Future studies will have to determine
whether such agents have a place in the prophylaxis or treatment of fever attacks in
HIDS.
In chapter 6 an other potential target for treatment was identified. Having identified
MK deficiency as the cause of HIDS, we studied whether cysteinyl leukotrienes,
known to be involved in the fever attacks of MA, were also involved in HIDS. From
the urinary excretion of LTE4 it appeared that cysteinyl leukotrienes were indeed
overproduced in HIDS, but only during fever attacks. The source of these lipid
mediators was not studied, but given the data presented in chapter 4, mononuclear
phagocytes could well be involved. LTE4 excretion has been described in other severe
inflammatory states, such as Kawasaki’s disease (32), and is by no means specific for
HIDS. It is to be regarded as one of the many effector mechanisms reflecting
uncontrolled macrophage activation. However, cysteinyl leukotrienes are potent pro-
inflammatory mediators and may well contribute to the symptoms of HIDS. Since
specific leukotriene antagonists have become available and have been found to be safe
in children (33), a trial of these agents may be warranted. Alternatively, dietary
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measures reducing the generation of cysteinyl leukotrienes, e.g. by adding fish
oil(34), might be worthwhile exploring.
Having addressed the pathogenesis of inflammation in HIDS, we then asked why
inflammation in this disease is episodic, rather than continuous. As described in
Chapter 7, it turns out that in HIDS, the mutated MK protein is synthesized even less
effectively when temperature is raised. This leads to a worsening of MK deficiency.
The activity of the preceding enzyme, HMG-CoA reductase, may be increased to
offset the effect of MK deficiency on isoprenoid biosynthesis. However, when MK
deficiency is profound (as in Mevalonic aciduria) or drops suddenly (as in HIDS at
higher temperatures) MK becomes rate limiting. Raised body temperature is common
in response to immunizations, viral infections and strenuous exercise, the usual
triggers of fever attacks in HIDS. We therefore hypothesize, that, in vivo, myeloid
cells, possibly activated via T-lymphocytes, are exposed to raised body temperature.
This would then lead to a progressive MK deficiency, resulting in a shortage of non-
sterol isoprenoids, which we think leads to a failure to limit activation of myeloid
cells in HIDS. The absence of inflammation between attacks would be explained by
the compensatory up regulation of HMG-CoA reductase, resulting in elevated
intracellular mevalonate levels. Once, upon an inflammatory trigger, this
compensation fails, inflammation, fever and enzyme deficiency spiral out of control.
Figure 4
Current understanding of the pathogenesis of HIDS
Summary and general discussion
15
In recent years our understanding of the pathogenesis of HIDS has improved
considerably (fig.4), but precise mechanisms linking isoprenoid biosynthesis and
inflammation have remained elusive. However, it is vital that these be uncovered.
HIDS and MA are troublesome, but rare. Autoinflammatory diseases in general are
troublesome and not rare. It is in this group of diseases that the control of normal
healthy defense mechanisms, i.e. innate immunity and non-specific inflammation,
fails. The persistence of such response patterns, which had evolved only to deal with
acute microbial threats, becomes deleterious to the host. The devastating effects of
chronic inflammation in autoinflammatory disorders are well known and our
therapeutic arsenal is often insufficient. The study of “experiments of nature” such as
HIDS, should uncover physiologic mechanisms that prevent inflammation becoming
chronic. Ultimately, knowledge gained in these rare diseases should lead to better
treatment options for both HIDS and the more common autoinflammatory disorders.
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Samenvatting
Koorts is meestal het gevolg van een infectieziekte. In zeldzamere gevallen leidt auto-
immuniteit, de respons van het afweersysteem op lichaamseigen bestanddelen, tot
koorts Er zijn echter patiënten bij wie koorts en andere ontstekingsverschijnselen
optreden die niet berusten op infectie of autoimmuniteit. Deze aandoeningen kunnen
aangeboren of verworven zijn en staan bekend als autoinflammatoire ziekten. De
aangeboren autoinflammatoire ziekten kenmerken zich door recidiverende
koortsaanvallen. De bekendste van deze hereditaire periodieke koortssyndromen was
de familiale mediterrane koorts (FMF), die voornamelijk voorkomt bij mensen wiens
voorouders uit het nabije oosten stammen. Begin jaren 80 van de vorige eeuw (1;2),
werd duidelijk dat er in onze streken een niet-mediterraan erfelijk syndroom met
periodieke koorts bestond, waarbij het immunoglobuline IgD, een eiwit met
onbekende functie, in het serum sterk verhoogd was. Het betrof patiënten die vanaf de
kinderleeftijd regelmatig, elke 2 tot 12 weken, een koortsaanval doormaakten die
acuut begon, een dag of drie aanhield en gepaard ging met huiduitslag,
gewrichtspijnen, braken, buikpijn, diarree en een opvallende lymfeklierzwelling.
Sedertdien is onze kennis over dit HyperIgD periodieke koorts syndroom (HIDS) of
Dutch type Periodic Fever (DPF) sterk toegenomen. De klinische verschijnselen en
het autosomaal recessieve erfelijkheidspatroon waren nauwkeurig in kaart gebracht
(3). Daarentegen bleven de drie kernverschijnselen van het syndroom, te weten de
verhoging van serum immunoglobulinen A en D, de gegeneraliseerde ontsteking
gepaard met hoge koorts en het optreden van ziekteverschijnselen in aanvallen,
onbegrepen. Effectieve behandeling was niet voorhanden. Onderzoek naar het
mechanisme van de ontsteking bracht een toegenomen activiteit aan het licht van pro-
inflammatoire cytokinen, zoals Interferon (IFN)-γ, Tumor Necrose Factor (TNF)-α,
Interleukine (IL)-1β and IL-6 (4-8).
In 1999, werd duidelijk dat tekort aan mevalonaat kinase tot HIDS kon leiden (9;10).
Mevalonaat kinase is een vroeg enzym in de isoprenoid biosynthese, de biochemische
route waarmee onder andere cholesterol wordt geproduceerd. De ontdekking dat een
aangeboren stofwisselingsdefect aan de ontstekingsziekte HIDS ten grondslag lag,
riep mogelijk meer vragen op dan zij beantwoordde (11). Wat was nu precies de
relatie tussen mevalonaat kinase deficiëntie en HIDS? Wordt HIDS altijd door
mevalonaat kinase deficiëntie veroorzaakt? Leidt mevalonaat kinase deficiëntie altijd
tot HIDS? En hoe leidt dit stofwisselingsdefect tot gegeneraliseerde ontsteking? Komt
dat door ophoping van het substraat (mevalonaat) of een tekort aan een van de vele
producten van de isoprenoid biosynthese (fig.1)? In welke cellen of weefsels sorteert
deze metabole ontregeling haar inflammatoire effect?.Zijn er, naast wat reeds bekend
was, nog meer ontstekingsmechanismen betrokken bij deze ziekte? En hoe kan een
persisterend metabool defect tot aanvalsgewijze ziekteverschijnselen leiden?
Deze vragen waren het onderwerp van het beschreven onderzoek
Figuur 1
Schematische weergave van de isopremoïd biosynthese.
Het biochemische pad voert van acetyl-CoA en acetoacetyl-CoA tot een veelheid van
eindproducten. Naast cholesterol levert deze route ook non-sterol isoprenoïden als
isopentenyl groepen, farnesyl-groepen, dolichol, ubiquinon-10 en haem-A. Het
metabole defect bij HIDS is onmiddellijk na HMG-CoA reductase, ter plaatse van
mevalonaat kinase.
In hoofdstuk 2, beschrijven wij een groep kinderen met HIDS (12). Het bleek dat niet
alle HIDS patiënten aan mevalonaat kinase deficiëntie leden. Ongeveer 80% van de
onderzochte patiënten hadden volledig normale activiteit van het enzym. Inmiddels is
deze bevinding ook bij volwassen patiënten bevestigd (13). De klinische kenmerken
maken geen onderscheid mogelijk tussen HIDS met en HIDS zonder mevalonaat
kinase deficiëntie Desondanks komen sommige verschijnselen, zoals begin van de
ziekte op de zuigelingenleeftijd, huiduitslag en diarree, meer voor bij de patiënten met
mevalonaat kinase deficiëntie. Deze groep wordt aangeduid als HIDS in engere zin of
DPF. Een verhoogd serum IgD is klaarblijkelijk niet specifiek voor mevalonaat kinase
deficiëntie. Integendeel, bij alle hereditaire periodieke koorts syndromen en ook bij
niet-erfelijke autoinflammatoire ziektebeelden als het. Periodieke koorts, adenitis,
faryngitis, stomatitis aftosa (PFAPA) syndroom (14) zijn patiënten beschreven met
een verhoogd serum IgD(15;16). Het is dan ook niet verwonderlijk dat het serum IgD
verhoogd kan zijn bij patiënten met periodieke koorts bij wie vooralsnog geen
syndroomdiagnose mogelijk is. Het opvallende aan HIDS in engere zin, is echter dat
het serum IgD veel vaker verhoogd is dan bij andere ziektebeelden. Het is niet bekend
hoe bij mevalonaat kinase deficiëntie een stijging van het serum IgD wordt
veroorzaakt. Uiteindelijk zal inzicht in het onderliggende mechanisme licht kunnen
doen schijnen op het verband tussen isoprenoïd biosynthese en het immuunsysteem.
Het serum IgD is overigens niet bij alle mevalonaat kinase deficiënte patiënten
verhoogd (17) (9). Daarmee ontstaat een semantisch probleem. Verschillende
pathologische entiteiten worden met één term (HIDS) aangeduid. Omgekeerd worden
de uiteenlopende uitingsvormen van mevalonaat kinase deficiëntie juist verschillend
benoemd.
Dat laatste wordt belicht in hoofdstuk 3. Immers, naast de patiënten met periodieke
koorts en gegeneraliseerde ontstekingsverschijnselen, al of niet met een hoog serum
IgD, zijn er die tevens pre- en postnatale groeivertraging hebben, achterblijven in
neurologische ontwikkeling en gelaatsmisvormingen vertonen. Dit laatste fenotype
staat bekend als mevalon acidurie (MA) (18). Wij konden aantonen dat er unieke
mutaties voorkwamen bij HIDS die niet bij mevalon acidurie patiënten werden
aangetroffen (19). All HIDS patiënten hadden een MVK-gen met de mutatie 1129
G>A die codeert voor de aminozuur substitutie V377I. Bij MA patiënten kwam deze
mutatie niet voor. Het eiwit met de V377I verandering geeft een minder diepe
mevalonaat kinase deficiëntie dan de eiwitveranderingen die werden aangetroffen bij
mevalon acidurie patiënten. Klaarblijkelijk is het deze relatief milde mevalonaat
kinase deficiëntie die tot het HIDS fenotype leidt. Overigens zijn HIDS en MA
waarschijnlijk uitersten van een klinisch continuüm. Zo zijn er patiënten met HIDS op
basis van milde enzymdeficiëntie die desondanks wel degelijk mentaal geretardeerd
zijn. Het viel op dat slechts enkele HIDS patiënten homozygoot waren voor de V377I
mutatie. Waarschijnlijk ontsnappen de meeste van hen aan de aandacht van medici en
het is aannemelijk dat vele van hen geheel klachtenvrij zijn.
Mevalonaat kinase deficiëntie leidt zowel tot een ophoping van het substraat,
mevalonzuur, als tot een verminderde productie van isoprenoïden (fig.1).
Welke van deze twee veranderingen leidt tot ontsteking werd onderzocht in
hoofdstuk 4. In een ex-vivo model, bepaalden wij de IL-1β secretie van normale
geïsoleerde mononucleaire witte bloedcellen na stimulatie via de aanwezige T-
lymfocyten. In dit model leidde reductie van de isoprenoïd productie tot en
toegenomen IL-1β secretie. Blootstelling aan mevalonaat leidde daarentegen niet tot
verhoogde IL-1 β secretie. Cellen van HIDS patiënten lieten juist een vermindering
van de IL-1β secretie zien in aanwezigheid van mevalonaat. Een soortgelijke
vermindering in IL-1β secretie namen wij waar wanneer de blokkade in isoprenoïd
biosynthese werd omzeild. Dat kon door aan de cellen metabolieten toe te voegen die
stroomafwaarts van de belemmering in de biochemische route kunnen instromen. De
beschikbaarheid van mevalonaat, dat stroomopwaarts van de belemmering bij HIDS
het pad instroomt, bleek onverwacht van cruciaal belang voor de cellen van HIDS. De
IL-1β secretie door deze cellen nam niet alleen af bij toevoeging van mevalonaat, zij
nam ook toe, wanneer de mevalonaat productie werd onderdrukt door lovastatine.
Deze waarneming geeft aan dat de behandeling van mevalonaat kinase deficiëntie
zich zou moeten richten op het herstel van isoprenoïd productie in plaats van op de
reductie van mealonaat productie.Het blijft op dit moment onduidelijk aan welke van
de vele producten van de isoprenoïd biosynthese een dusdanig tekort ontstaat dat
ontstekingsverschijnselen optreden. A fortiori is het onduidelijk hoe een dergelijk
tekort tot ontsteking leidt.
Evenmin was duidelijk waar, dat wil zeggen in welk weefsel of celtype, belemmering
van de isoprenoïd biosynthese tot ontsteking leidde.
In hoofdstuk 5 onderzochten wij daarom leukocyten van HIDS patiënten tijdens
koorts aanvallen en in aanvalsvrije episoden. Het was van verscheidene leukocyten
subpopulaties denkbaar dat zij geactiveerd zouden zijn bij deze aandoening. Activatie
van B-lymfocyten kon worden verwacht op grond van de polyclonale verhoging van
serum IgD en IgA bij HIDS (20). Betrokkenheid van T-lymfocyten, was reeds
vermoed vanwege de hoge serum concentratie van interferon-gamma tijdens
koortsaanvallen(6). Mononucleaire fagocyten konden worden verondersteld
geactiveerd te zijn. Immers, verhoogde productie van ontstekingsmediatoren
afkomstig van deze celpoplatie waren zowel in- als ex-vivo waargenomen bij HIDS
patiënten (7;8). Ook de verhoogde excretie van neopterine en Leukotrïeen-E4 in de
urine wees op activatie van mononucleaire fagocyten (8)(hoofdstuk 6). Betrokkenheid
van neutrofiele granulocyten kon worden vermoed, aangezien granulocytose tijdens
de koortsaanvallen van HIDS regel is (3). Hoewel er discrete aanwijzingen voor T-cel
activatie waren, vielen vooral de veraderingen onder de myeloïde cellen op. Het
aantal neutrofiele granulocyten was verviervoudigd, het aantal monocyten
verdrievoudigd. Bovendien waren deze cellen geactiveerd, zoals bleek uit de
verhoogde expressie van het oppervlakte-molecuul CD64. Hiermee is nog niet
aangetoond dat myeloïde cellen als eerste geactiveerd worden bij de
ontstekingsepisoden van HIDS. Mogelijk worden deze leukocyten indirect
geactiveerd door een andere celpopulatie, zoals T-cellen of niet-circulerende cellen of
weefsels. Echter, een centrale rol voor granulocyten en monocyten zou overeen
komen met hetgeen bij de andere erfelijke periodieke koorts syndromen is gevonden.
In hoofdstuk 6 onderzochten wij of cysteinyl leukotriënen, ontstekingsmediatoren
betrokken bij de koortsaanvallen van mevalon acidurie, ook een rol speelden bij het
mildere fenotype van mevalonaat kinase deficiëntie, HIDS. Uit de verhoogde
concentratie van leukotrïeen-E4 (LTE4 )in de urine kon worden geconcludeerd dat dit
tijdens koortsepisoden het geval was. Welke cellen of weefsels deze mediatoren
produceerden werd niet onderzocht, maar, gezien de bevindingen in hoofdstuk 4, is
het plausibel dat mononucleaire fagocyten hiervoor verantwoordelijk zijn. Cysteinyl
leukotriënen zijn krachtige pro-inflammatoire mediatoren, die waarschijnlijk
substantieel bijdragen aan de klinische verschijnselen van HIDS-patiënten. Aangezien
er tegenwoordig veilige en effectieve leukotrïeen antagoniten beschikbaar zijn, lijkt
een studie naar het  effect van dergelijke middelen bij HIDS zinvol.
Ten slotte onderzochten wij, waardoor de onstekingsverschijnselen bij deze
aandoening periodiek in plaats van continu zijn. Het blijkt, zoals beschreven in
hoofdstuk 7, dat het mutante mevalonaat kinase eiwit van HIDS patiënten niet
effectief kan worden aangemaakt wanneer de temperatuur toeneemt. Het resultaat is
een verergering van de mevalonaat kinase deficiëntie. Dit werd zowel in-vitro als in-
vivo waargenomen. De activiteit van het voorafgaande enzym, HMG-CoA reductase,
kan toenemen om te compenseren voor het effect van mevalonaat kinase deficiëntie
op de isoprenoïd biosynthese. Echter, bij diepe mevalonaat kinase deficiëntie (zoals
bij patiënten met mevalon acidurie) of bij een plotselinge afname van de mevalonaat
kinase-activiteit (zoals bij HIDS, wanneer de temperatuur oploopt), wordt mevalonaat
kinase de flessenhals van deze biosynthetische route. Verhoogde lichaamstemperatuur
kan het gevolg zijn van infecties, inentingen of zware lichamelijke inspanning,
omstandigheden waarvan bekend is dat zij vaak aanvallen bij HIDS-patiënten
uitlokken.
Gezien het voorgaande veronderstellen wij, dat myeloïde cellen, al dan niet
geactiveerd via T-cellen, in vivo bloot worden gesteld aan een verhoogde
lichaamstemperatuur. Dit resulteert in een progressieve mevalonaat kinase deficiëntie,
waardoor een tekort ontstaat aan bepaalde isoprenoïden. Dit tekort veroorzaakt op
haar beurt een ongecontroleeerde activatie van myeloïde cellen. Het ontbreken van
ontstekingsverschijnselen tussen de aanvallen zou mogelijk kunnen worden verklaard
door een compensatoire verhoging van de HMG-CoA reductase activiteit. Wanneer
deze compensatie, als gevolg van een inflammatoire stimulus, tekort schiet, zou een
vicieuze cyclus kunnen ontstaan van koorts, enzym deficiëntie en ontsteking.
Hoewel onze kennis van de pathogenese van HIDS in de afgelopen jaren belangrijk is
toegenomen, kennen wij het precieze mechanismen die gestoorde isoprenoïd
biosynthese met ontsteking verbindt nog niet. Het is echter essentieel dat deze worden
opgehelderd. Alleen op die manier kan een effectieve behandeling voor deze andening
worden gevonden. Nu is die nog niet oorhanden.
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3Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS; MIM 260920) is an
autosomal recessive disorder characterized by recurrent episodes of fever associated
with lymphadenopathy, arthralgia, gastrointestinal dismay and skin rash (1;2).
Diagnostic hallmark of HIDS is a constitutively elevated level of serum immunoglobulin
D (IgD) although patients have been reported with normal IgD levels(2). In search for
the underlying defect in HIDS, we analyzed urine of several patients and discovered
increased concentrations of mevalonic acid during severe episodes of fever but not in
between crises. Subsequent analysis of cells from four unrelated HIDS patients revealed
strongly reduced activities of mevalonate kinase (MK), a key enzyme of isoprenoid
biosynthesis. Sequence analysis of the patients’ MK cDNAs identified three different
mutations of which one was common to all four patients. Expression of the mutant
cDNAs in Escherichia coli showed that all three mutations affect the activity of the
encoded proteins. Moreover, immunoblot analysis demonstrated a deficiency of MK
protein in patients’ fibroblasts indicating a protein destabilizing effect of the mutations.
The identification of an enzyme defect in isoprenoid biosynthesis in patients with
periodic fever and dysregulation of their immune system creates new challenges for the
elucidation of the pathogenesis of periodic fever.
On performing organic acid analysis of urine and, subsequently, plasma from an 18-year
old patient obtained during a severe episode of fever we noticed significantly increased
concentrations of mevalonic acid (patient 1; Table 1 and 2). Because this patient had suffered
from recurrent episodes of fever associated with clinical signs characteristic of HIDS since
the age of 16 months (although he never displayed elevated serum IgD levels), we examined
two additional patients clinically diagnosed with HIDS (patients 2 and 3; Table 1). These
patients also showed increased concentrations of mevalonic acid in their urine during but not
in between episodes of fever (Table 2).
4Table 1 • Clinical features of the four HIDS patients and clinical features
characteristic for HIDS and mevalonic aciduriaa
Clinical features       Patient number   HIDSb Mevalonic aciduriac
 1  2  3  4
Recurrent fevers  +  +  +  +      +             +
Lymphadenopathy  +  +  +  +      +             +
Skin lesions/rash  +  +  +  +      +             +
Abdominal pain/diarrhea  +  +  +  +      +             +
Arthralgia  +  +  +  +      +             +
Psychomotor retardation  −  +  −  −      −             +/+++
Failure to thrive  −  −  −  −      −             +/+++
Hypotonia/myopathy  +  −  −  −      −             −/++
Ataxia/cerebellar atrophy  −  −  −  −      −             −/+++
Hepatomegaly  +  −  −  +      −             −/+
Cataracts  −  −  −  −      −             −/+
Dysmorphic features  −  −  −  −      −             −/+
Age of onset (months) 16  3  7 15
Serum IgD (U/ml)   Min. 12 960  222 47   >100              ?
                               Max. 32 4244  350 192
a, symbols used: +, present; ++, moderate; +++, severe; −, absent; ?, unknown;
b, adapted from ref. 2; c, adapted from ref. 6.
5The increased concentrations of mevalonic acid suggested a defect in the metabolism of
mevalonate, which is the physiological substrate of mevalonate kinase (MK). This dimeric
protein, reported to be localized in both cytosol and peroxisomes (3), is a key enzyme of
isoprenoid biosynthesis and catalizes the phosphorylation of mevalonate to produce 5-
phosphomevalonate (4). When we measured the activity of MK in lymphocytes of four HIDS
patients we found markedly reduced activities ranging from 1.3 to 3.2% of the mean activity
measured in control lymphocytes (Table 2). Analysis of lymphocytes of the parents of
patients 1, 2 and 3 showed intermediate MK activities ranging from 22 to 46% of the mean
activity in control lymphocytes and indicating heterozygosity for the defect which is in
accordance with the presumed autosomal recessive inheritance of HIDS.
6Table 2 • Biochemical data and mutations of HIDS patients and their relatives
Individual Urinary
Mevalonic acida
MK activity in
lymphocytesb
Mutation Coding effect
Control subjects 0.08-0.3 95.8±17.0 − −
HIDS patient 1 8.3-9.6 2.0 (2.1%) 59A>C
1129G>A
H20P
V377I
    Mother ND 21.1 (22%) 59A>C H20P
    Father ND 44.0 (46%) 1129G>A V377I
    Sister ND 30.5 (32%) 1129G>A V377I
    Brother ND 117 (122%) no mutation −
HIDS patient 2 6.4 1.3 (1.2%) 59A>C
1129G>A
H20P
V377I
    Mother ND 24.1 (25%) ND −
    Father ND 38.7 (41%) ND −
HIDS patient 3 5.3-27.8 1.9 (2%) 803T>C
1129G>A
I268T
V377I
    Mother ND 31.0 (33%) ND −
    Father ND 25.4 (27%) ND −
HIDS patient 4 ND 3.3 (3.4%) 1129G>A V377I
a, mmol/mol creatinine; b, pmol/min/mg protein; ND, not determined.
7The combination of a deficient MK activity and increased concentrations of excreted
mevalonic acid, but then constitutive and much more massive, are also characteristic for
mevalonic aciduria (MIM 251170), a rare and severe, progressive, multi-systemic disorder
associated with periodic fever and caused by mutations in the gene encoding MK (5-8). To
determine the relationship between HIDS and mevalonic aciduria, we measured the MK
activities in cultured skin fibroblasts from HIDS patients 1, 2 and 3 and two patients with
mevalonic aciduria. Virtually no MK activity was detected in the cells of both mevalonic
aciduria patients (0.2% residual activity) while the activities in the cells of the HIDS patients
ranged from 0.8 to 3.6% of the mean activity measured in control fibroblasts.
Sequence analysis of RT-PCR amplified MK cDNAs identified the same 1129G>A
mutation in all four HIDS patients (Table 2). Patients 1 to 3 were compound heterozygous for
this mutation and an additional missense mutation, while patient 4 appeared homozygous for
the 1129G>A mutation. However, it can not be excluded at present that this latter patient is
compound heterozygous for this mutation and a second mutation that produces an unstable
mRNA. The 1129G>A mutation changes the valine at position 377 of the MK amino acid
sequence (7) into an isoleucine (V377I). Comparison of the human MK amino acid sequence
to the sequences of rat and mouse MK (82% and 81% identity with human MK, respectively)
revealed that this valine is fully conserved (not shown). Nevertheless, to exclude that this
relatively mild conversion was due to a common polymorphism, we analyzed MK cDNAs of
24 control subjects, including 15 subjects of Dutch origin, for the presence of this V377I
allele and did not detect any. The two additional missense mutations identified in patients 1
and 2 (59A>C) and in patient 3 (803T>C) change the histidine at position 20 into a proline
(H20P) and the isoleucine at position 268 into a threonine (I268T), respectively. All three
mutations differ from the two previously reported mutations causing mevalonic aciduria
8(N301T and A334T) (7;8). The autosomal recessive nature of the disorder was confirmed by
the heterozygous presence of one of the two mutations of patient 1 in the MK cDNAs of his
symptom-free parents and sister (Table 2) and fits with the reported location of the MK gene
on chromosome 12 (Ref. 7).
The identification of the same V377I allele in the four unrelated HIDS patients strongly
suggested that this allele is responsible for the presentation of HIDS. Furthermore, the
residual MK activity measured in cells of these patients suggested that the V377I allele
produces a mutant MK protein with either a strongly reduced activity or stability or both.
Therefore, we first examined the effect of the different mutations on the MK activity by
means of expression of the wild type and the three mutant proteins as a fusion to glutathione
S-transferase (GST) in Escherichia coli. Previously, it had been shown that this fusion
stabilizes the MK enzyme and hardly changes its kinetic properties when compared to MK
purified from liver(8). An additional advantage of this approach is that the MK activities can
be normalized for the activities of GST to allow direct comparison between the wild type and
mutant enzymes. The enzyme measurements in E. coli lysates showed that both the H20P and
the I268T mutation have a dramatic effect on the activity of the respective MK proteins (Fig.
1).
90% 20% 40% 60% 80% 100%
H20P
I268T
V377I
WT
Percentage residual MK activity
Fig. 1 Expression of MK cDNAs in Escherichia coli. The coding sequences of wild type and
mutant MK cDNAs were amplified by RT-PCR and expressed as a fusion with glutathione S-
transferase (GST) in E. coli. The MK enzyme activities were measured in E. coli lysates and
normalized for GST enzyme activities to correct for differences in expression. MK/GST
activity ratios of the mutant fusion proteins are presented as the percentage of the mean ratio
of the wild type fusion protein. The results are the mean of four independent measurements.
The V377I mutation also causes a significant decrease in the MK activity, but the relative
residual activity was still approximately ten fold higher than the activity measured in the cells
of the HIDS patients. However, when we performed immunoblot analysis of fibroblast lysates
of the patients, we hardly detected any MK protein while in lysates of control fibroblasts the
protein is readily visible (Fig. 2). Together, these results indicate that although the V377I
mutation has some effect on the enzyme activity, it predominantly affects the stability of the
MK protein.
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Fig. 2 Immunoblot analysis of fibroblast lysates of HIDS patients. Cell lysates of cultured
skin fibroblasts of three control subjects and HIDS patients 1, 2 and 3 were resolved by SDS-
PAGE (100 µg of total protein per lane), blotted onto nitrocellulose and analyzed with a
polyclonal antibody against human MK. For reference, a liver cell lysate from a control
subject (40 µg of total protein) is included.
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In conclusion, our results indicate that HIDS is the consequence of a strongly reduced but
not completely deficient activity of mevalonate kinase and therefore could be considered as a
mild presentation of mevalonic aciduria. This also is apparent when the clinical features
associated with HIDS are compared to those associated with mevalonic aciduria (Table 1).
The fact that one of the HIDS patients did not have an elevated level of serum IgD indicates
that this elevation, which is often associated with HIDS, is an epiphenomenon.
The unexpected discovery of a metabolic defect in the isoprenoid biosynthesis in patients
with periodic fever and a dysregulation of their immune system creates new challenges for the
understanding and elucidation of the processes underlying periodic fever or fever in general.
Isoprenoids are important intermediates in the generation of several classes of compounds,
including sterols, dolichol, ubiquinone and prenylated proteins, which can be involved in a
variety of cellular processes such as cell growth and differentation, glycosylation, signal
transduction and electron transport (4). At this moment, it is unclear which of these processes
are linked to the pathogenesis of HIDS or to other syndromes associated with periodic fever
such as systemic juvenile rheumatoid arthritis, familial Mediterranean fever and familial
Hibernian fever (9).
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Methods
Patients. All patients used in this study were unrelated to each other and of Dutch origin
except for patient 3 who had a father of Indonesian origin. Patients 1-3 were male and patient
4 female. The diagnosis of HIDS was based on clinical signs and, except for patient 1,
elevated serum IgD levels (Table 1).
Mevalonic acid measurements. Concentrations of mevalonic acid in urine and plasma were
determined by stable isotope dilution gas chromatography - mass spectrometry of the
trimethylsilyl ether esters using 2H7-mevalonolactone (C/D/N Isotope Inc) as internal standard
(10).
Enzyme assays. MK was measured using 14C-labeled mevalonate as the substrate (11).
Gluthione-S-transferase activity was assayed on a spectrophotometer at 335 nm by measuring
the formation of the conjugate of glutathione and 1-chloro-2,4-dinitrobenzene (12)
Mutation analysis of human MK cDNA. First strand cDNA was prepared from total RNA
isolated from lymphocytes or fibroblasts as described (13). Two sets of MK-specific primers
with -21M13 or M13rev extensions were used to amplify MK cDNA in two overlapping
fragments by RT-PCR. The PCR fragments were sequenced in both directions by means of -
21M13 and M13rev fluorescent primers on an ABI 377A automated DNA sequencer
according to the manufacturer’s protocol (Perkin-Elmer).
Expression of mevalonate kinase cDNAs in E. coli. The coding sequences of wild type and
mutant MK cDNAs were amplified by PCR, cloned in frame with the coding sequences of
gluthathione-S-transferase in pGEX-4T (Pharmacia) and sequenced to exclude Taq
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polymerase introduced errors. E. coli DH5α cells were transformed with the resulting
expression plasmids, induced for 2 hours with 2 mM IPTG and subsequently lysed by
sonication.
Antibody preparation and immunoblot analysis. A synthetic peptide corresponding to
amino acid residues 76 to 90 of human mevalonate kinase7 was conjugated with keyhole
limpet hemocyanin and used to produce antibodies in a rabbit (Eurogentech). The crude
antiserum was affinity-purified on a column containing MK-GST coupled to cyanogen
bromide sepharose (Pharmacia). For immunoblot analysis, the affinity-purified antibodies
were used at a 1:100 dilution and antigen-antibody complexes were visualized using anti-IgG-
alkaline phosphatase conjugate.
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